Background  ||| S:24 E:43 ||| NN
Although  ||| S:43 E:52 ||| IN
the  ||| S:52 E:56 ||| DT
role  ||| S:56 E:61 ||| NN
of  ||| S:61 E:64 ||| IN
the  ||| S:64 E:68 ||| DT
osteoclast  ||| S:68 E:79 ||| NN
in  ||| S:79 E:82 ||| IN
bone  ||| S:82 E:87 ||| NN
resorption  ||| S:87 E:106 ||| NN
is  ||| S:106 E:109 ||| VBZ
becoming  ||| S:109 E:118 ||| VBG
better  ||| S:118 E:125 ||| JJR
understood  ||| S:125 E:136 ||| NNS
[  ||| S:136 E:138 ||| -LRB-
1 ||| S:138 E:139 ||| LS
] ||| S:139 E:140 ||| -RRB-
,  ||| S:140 E:142 ||| ,
much  ||| S:142 E:147 ||| RB
remains  ||| S:147 E:155 ||| VBZ
to  ||| S:155 E:158 ||| TO
be  ||| S:158 E:169 ||| VB
learned  ||| S:169 E:177 ||| VBN
about  ||| S:177 E:183 ||| IN
osteoclastogenesis  ||| S:183 E:202 ||| NN
and  ||| S:202 E:206 ||| CC
the  ||| S:206 E:210 ||| DT
exact  ||| S:210 E:216 ||| JJ
mechanism  ||| S:216 E:226 ||| NN
of  ||| S:226 E:237 ||| IN
action  ||| S:237 E:244 ||| NN
of  ||| S:244 E:247 ||| IN
anti-resorbing  ||| S:247 E:262 ||| JJ
agents  ||| S:262 E:269 ||| NNS
on  ||| S:269 E:272 ||| IN
the  ||| S:272 E:276 ||| DT
functional  ||| S:276 E:295 ||| JJ
osteoclast ||| S:295 E:305 ||| NN
.  ||| S:305 E:307 ||| .
The  ||| S:307 E:311 ||| DT
anti-resorbing  ||| S:311 E:326 ||| JJ
agent  ||| S:326 E:332 ||| NN
17β-estradiol  ||| S:332 E:346 ||| NN
is  ||| S:346 E:357 ||| VBZ
especially  ||| S:357 E:368 ||| RB
noteworthy  ||| S:368 E:379 ||| VBN
because  ||| S:379 E:387 ||| IN
of  ||| S:387 E:390 ||| IN
the  ||| S:390 E:394 ||| DT
association  ||| S:394 E:406 ||| NN
of  ||| S:406 E:409 ||| IN
its  ||| S:409 E:421 ||| PRP$
decline  ||| S:421 E:429 ||| NN
at  ||| S:429 E:432 ||| IN
menopause  ||| S:432 E:442 ||| NN
with  ||| S:442 E:447 ||| IN
the  ||| S:447 E:451 ||| DT
development  ||| S:451 E:463 ||| NN
of  ||| S:463 E:466 ||| IN
postmenopausal  ||| S:466 E:489 ||| JJ
osteoporosis ||| S:489 E:501 ||| NN
.  ||| S:501 E:503 ||| .
As  ||| S:503 E:506 ||| RB
previously  ||| S:506 E:517 ||| RB
noted  ||| S:517 E:523 ||| VBD
by  ||| S:523 E:526 ||| IN
Liu  ||| S:526 E:530 ||| NNP
and  ||| S:530 E:534 ||| CC
Howard ||| S:534 E:540 ||| NNP
,  ||| S:540 E:542 ||| ,
the  ||| S:542 E:554 ||| DT
underlying  ||| S:554 E:565 ||| JJ
cellular  ||| S:565 E:574 ||| JJ
changes  ||| S:574 E:582 ||| NNS
responsible  ||| S:582 E:594 ||| VBP
the  ||| S:594 E:598 ||| DT
increased  ||| S:598 E:608 ||| JJ
bone  ||| S:608 E:621 ||| NN
formation  ||| S:621 E:631 ||| NN
which  ||| S:631 E:637 ||| WDT
follows  ||| S:637 E:645 ||| VBZ
estrogen  ||| S:645 E:654 ||| JJ
administration  ||| S:654 E:669 ||| NN
are  ||| S:669 E:673 ||| VBP
still  ||| S:673 E:687 ||| RB
not  ||| S:687 E:691 ||| RB
well  ||| S:691 E:696 ||| RB
characterized  ||| S:696 E:710 ||| VBN
[  ||| S:710 E:712 ||| -LRB-
2 ||| S:712 E:713 ||| LS
] ||| S:713 E:714 ||| -RRB-
.  ||| S:714 E:724 ||| .
In  ||| S:724 E:727 ||| IN
the  ||| S:727 E:731 ||| DT
present  ||| S:731 E:739 ||| JJ
report  ||| S:739 E:746 ||| NN
we  ||| S:746 E:749 ||| PRP
report  ||| S:749 E:756 ||| VBP
findings  ||| S:756 E:765 ||| NNS
on  ||| S:765 E:768 ||| IN
alterations  ||| S:768 E:788 ||| NN
in  ||| S:788 E:791 ||| IN
osteoclast  ||| S:791 E:802 ||| JJ
morphology  ||| S:802 E:813 ||| NNS
following  ||| S:813 E:823 ||| VBG
long  ||| S:823 E:828 ||| JJ
term  ||| S:828 E:833 ||| NN
administration  ||| S:833 E:856 ||| NN
of  ||| S:856 E:859 ||| IN
high  ||| S:859 E:864 ||| JJ
doses  ||| S:864 E:870 ||| NNS
of  ||| S:870 E:873 ||| IN
17β-estradiol  ||| S:873 E:887 ||| CD
to  ||| S:887 E:890 ||| TO
B6D2F1  ||| S:890 E:897 ||| CD
mice ||| S:897 E:901 ||| NNS
.  ||| S:901 E:903 ||| .
Development  ||| S:903 E:923 ||| NN
of  ||| S:923 E:926 ||| IN
osteosclerosis  ||| S:926 E:941 ||| NN
and  ||| S:941 E:945 ||| CC
the  ||| S:945 E:949 ||| DT
disappearance  ||| S:949 E:963 ||| NN
of  ||| S:963 E:966 ||| IN
the  ||| S:966 E:970 ||| DT
marrow  ||| S:970 E:977 ||| JJ
space  ||| S:977 E:991 ||| NN
in  ||| S:991 E:994 ||| IN
these  ||| S:994 E:1000 ||| DT
estrogen-treated  ||| S:1000 E:1017 ||| JJ
mice  ||| S:1017 E:1022 ||| NNS
is  ||| S:1022 E:1025 ||| VBZ
an  ||| S:1025 E:1028 ||| DT
interesting  ||| S:1028 E:1040 ||| JJ
and  ||| S:1040 E:1044 ||| CC
useful  ||| S:1044 E:1059 ||| JJ
model  ||| S:1059 E:1065 ||| NN
since  ||| S:1065 E:1071 ||| IN
marrow  ||| S:1071 E:1078 ||| JJ
stromal  ||| S:1078 E:1086 ||| JJ
cells  ||| S:1086 E:1092 ||| NNS
not  ||| S:1092 E:1096 ||| RB
only  ||| S:1096 E:1101 ||| RB
contain  ||| S:1101 E:1109 ||| VB
the  ||| S:1109 E:1121 ||| DT
precursors  ||| S:1121 E:1132 ||| NN
for  ||| S:1132 E:1136 ||| IN
osteogenic  ||| S:1136 E:1147 ||| JJ
cell  ||| S:1147 E:1152 ||| NN
lineages ||| S:1152 E:1160 ||| NN
,  ||| S:1160 E:1162 ||| ,
but  ||| S:1162 E:1166 ||| CC
they  ||| S:1166 E:1171 ||| PRP
also  ||| S:1171 E:1184 ||| RB
exert  ||| S:1184 E:1190 ||| JJ
important  ||| S:1190 E:1200 ||| JJ
effects  ||| S:1200 E:1208 ||| NNS
on  ||| S:1208 E:1211 ||| IN
osteoclastogenesis  ||| S:1211 E:1230 ||| NN
and  ||| S:1230 E:1242 ||| CC
lymphopoiesis ||| S:1242 E:1255 ||| NN
,  ||| S:1255 E:1257 ||| ,
and  ||| S:1257 E:1261 ||| CC
modulate  ||| S:1261 E:1270 ||| VBP
the  ||| S:1270 E:1274 ||| DT
effects  ||| S:1274 E:1282 ||| NNS
of  ||| S:1282 E:1285 ||| IN
some  ||| S:1285 E:1290 ||| DT
systemic  ||| S:1290 E:1307 ||| JJ
factors  ||| S:1307 E:1315 ||| NNS
of  ||| S:1315 E:1318 ||| IN
bone  ||| S:1318 E:1323 ||| NN
turnover ||| S:1323 E:1331 ||| NN
.  ||| S:1331 E:1333 ||| .
Osteoclasts ||| S:1333 E:1344 ||| NNP
,  ||| S:1344 E:1346 ||| ,
as  ||| S:1346 E:1349 ||| RB
well  ||| S:1349 E:1354 ||| RB
as  ||| S:1354 E:1365 ||| IN
osteoblasts ||| S:1365 E:1376 ||| NN
,  ||| S:1376 E:1378 ||| ,
possess  ||| S:1378 E:1386 ||| FW
estrogen  ||| S:1386 E:1395 ||| FW
receptors  ||| S:1395 E:1405 ||| FW
[  ||| S:1405 E:1407 ||| -LRB-
3 ||| S:1407 E:1408 ||| LS
,  ||| S:1408 E:1410 ||| ,
4 ||| S:1410 E:1411 ||| CD
,  ||| S:1411 E:1413 ||| ,
5 ||| S:1413 E:1414 ||| CD
,  ||| S:1414 E:1416 ||| ,
6 ||| S:1416 E:1417 ||| CD
] ||| S:1417 E:1418 ||| -RRB-
.  ||| S:1418 E:1428 ||| .
Hematopoietic  ||| S:1428 E:1442 ||| JJ
cells  ||| S:1442 E:1448 ||| NNS
also  ||| S:1448 E:1453 ||| RB
influence  ||| S:1453 E:1463 ||| VB
osteogenic  ||| S:1463 E:1474 ||| JJ
cell  ||| S:1474 E:1487 ||| NN
differentiation ||| S:1487 E:1502 ||| NN
,  ||| S:1502 E:1504 ||| ,
and  ||| S:1504 E:1508 ||| CC
some  ||| S:1508 E:1513 ||| DT
evidence  ||| S:1513 E:1522 ||| NN
suggests  ||| S:1522 E:1531 ||| VBZ
that  ||| S:1531 E:1536 ||| DT
mature  ||| S:1536 E:1551 ||| JJ
lymphocytes  ||| S:1551 E:1563 ||| JJ
influence  ||| S:1563 E:1573 ||| NN
osteoclast  ||| S:1573 E:1584 ||| NNS
and  ||| S:1584 E:1588 ||| CC
osteoblast  ||| S:1588 E:1599 ||| JJ
function ||| S:1599 E:1607 ||| NN
.  ||| S:1607 E:1617 ||| .
In  ||| S:1617 E:1620 ||| IN
the  ||| S:1620 E:1624 ||| DT
estrogen-treated  ||| S:1624 E:1641 ||| JJ
mouse  ||| S:1641 E:1647 ||| NN
model  ||| S:1647 E:1653 ||| NN
used  ||| S:1653 E:1658 ||| VBN
in  ||| S:1658 E:1661 ||| IN
the  ||| S:1661 E:1665 ||| DT
studies  ||| S:1665 E:1681 ||| NNS
reported  ||| S:1681 E:1690 ||| VBD
here ||| S:1690 E:1694 ||| RB
,  ||| S:1694 E:1696 ||| ,
natural  ||| S:1696 E:1704 ||| JJ
killer  ||| S:1704 E:1711 ||| NN
( ||| S:1711 E:1712 ||| -LRB-
NK ||| S:1712 E:1714 ||| NNP
)  ||| S:1714 E:1716 ||| -RRB-
cells ||| S:1716 E:1721 ||| NNS
,  ||| S:1721 E:1723 ||| ,
which  ||| S:1723 E:1729 ||| WDT
rely  ||| S:1729 E:1734 ||| VBP
upon  ||| S:1734 E:1747 ||| IN
an  ||| S:1747 E:1750 ||| DT
intact  ||| S:1750 E:1757 ||| JJ
bone  ||| S:1757 E:1762 ||| NN
marrow  ||| S:1762 E:1769 ||| NN
for  ||| S:1769 E:1773 ||| IN
full  ||| S:1773 E:1778 ||| JJ
marrow  ||| S:1778 E:1785 ||| JJ
maturation ||| S:1785 E:1795 ||| NN
,  ||| S:1795 E:1797 ||| ,
are  ||| S:1797 E:1809 ||| VBP
arrested  ||| S:1809 E:1818 ||| VBN
in  ||| S:1818 E:1821 ||| IN
a  ||| S:1821 E:1823 ||| DT
nonlytic  ||| S:1823 E:1832 ||| JJ
state  ||| S:1832 E:1838 ||| NN
[  ||| S:1838 E:1840 ||| -LRB-
7 ||| S:1840 E:1841 ||| CD
] ||| S:1841 E:1842 ||| -RRB-
;  ||| S:1842 E:1844 ||| :
since  ||| S:1844 E:1850 ||| IN
marrow  ||| S:1850 E:1857 ||| JJ
space  ||| S:1857 E:1863 ||| NN
is  ||| S:1863 E:1874 ||| VBZ
lessened  ||| S:1874 E:1883 ||| JJ
due  ||| S:1883 E:1887 ||| JJ
to  ||| S:1887 E:1890 ||| TO
the  ||| S:1890 E:1894 ||| DT
osteosclerosis ||| S:1894 E:1908 ||| NN
,  ||| S:1908 E:1910 ||| ,
the  ||| S:1910 E:1914 ||| DT
spleen  ||| S:1914 E:1921 ||| NN
provides  ||| S:1921 E:1930 ||| VBZ
the  ||| S:1930 E:1942 ||| DT
source  ||| S:1942 E:1949 ||| NN
for  ||| S:1949 E:1953 ||| IN
T  ||| S:1953 E:1955 ||| NN
and  ||| S:1955 E:1959 ||| CC
B  ||| S:1959 E:1961 ||| NNP
cells  ||| S:1961 E:1967 ||| NNS
and  ||| S:1967 E:1971 ||| CC
macrophages ||| S:1971 E:1982 ||| NN
.  ||| S:1982 E:1992 ||| .
The  ||| S:1992 E:1996 ||| DT
objective  ||| S:1996 E:2006 ||| NN
of  ||| S:2006 E:2009 ||| IN
the  ||| S:2009 E:2013 ||| DT
present  ||| S:2013 E:2021 ||| JJ
study  ||| S:2021 E:2027 ||| NN
was  ||| S:2027 E:2031 ||| VBD
to  ||| S:2031 E:2034 ||| TO
assess  ||| S:2034 E:2041 ||| VB
the  ||| S:2041 E:2053 ||| DT
functional  ||| S:2053 E:2064 ||| JJ
state  ||| S:2064 E:2070 ||| NN
of  ||| S:2070 E:2073 ||| IN
osteoclasts  ||| S:2073 E:2085 ||| NN
in  ||| S:2085 E:2088 ||| IN
estrogen-treated  ||| S:2088 E:2105 ||| JJ
mice  ||| S:2105 E:2110 ||| NNS
by  ||| S:2110 E:2121 ||| IN
determining  ||| S:2121 E:2133 ||| VBG
if  ||| S:2133 E:2136 ||| IN
osteoclasts  ||| S:2136 E:2148 ||| NN
retained  ||| S:2148 E:2157 ||| VBD
tartrate-resistant  ||| S:2157 E:2176 ||| JJ
acid  ||| S:2176 E:2189 ||| NN
phosphatase  ||| S:2189 E:2201 ||| NN
activity  ||| S:2201 E:2210 ||| NN
( ||| S:2210 E:2211 ||| -LRB-
TRAP ||| S:2211 E:2215 ||| NNP
)  ||| S:2215 E:2217 ||| -RRB-
and  ||| S:2217 E:2221 ||| CC
normal  ||| S:2221 E:2228 ||| JJ
ultrastructural  ||| S:2228 E:2252 ||| JJ
features ||| S:2252 E:2260 ||| NNS
.  ||| S:2260 E:2284 ||| .
Results  ||| S:2284 E:2300 ||| NNS
Radiographic  ||| S:2300 E:2313 ||| JJ
examination  ||| S:2313 E:2325 ||| NN
of  ||| S:2325 E:2328 ||| IN
excised  ||| S:2328 E:2336 ||| JJ
specimens  ||| S:2336 E:2346 ||| NNS
from  ||| S:2346 E:2359 ||| IN
control  ||| S:2359 E:2367 ||| NN
and  ||| S:2367 E:2371 ||| CC
estradiol-treated  ||| S:2371 E:2389 ||| JJ
mice  ||| S:2389 E:2394 ||| NNS
confirmed  ||| S:2394 E:2404 ||| VBD
the  ||| S:2404 E:2408 ||| DT
presence  ||| S:2408 E:2425 ||| NN
of  ||| S:2425 E:2428 ||| IN
osteosclerosis  ||| S:2428 E:2443 ||| NN
in  ||| S:2443 E:2446 ||| IN
the  ||| S:2446 E:2450 ||| DT
femurs  ||| S:2450 E:2457 ||| NN
of  ||| S:2457 E:2460 ||| IN
estradiol-treated  ||| S:2460 E:2478 ||| JJ
mice ||| S:2478 E:2482 ||| NNS
.  ||| S:2482 E:2492 ||| .
Diaphyseal  ||| S:2492 E:2503 ||| JJ
cortices  ||| S:2503 E:2512 ||| NN
were  ||| S:2512 E:2517 ||| VBD
prominent  ||| S:2517 E:2527 ||| JJ
in  ||| S:2527 E:2530 ||| IN
the  ||| S:2530 E:2534 ||| DT
midshaft  ||| S:2534 E:2543 ||| NN
of  ||| S:2543 E:2554 ||| IN
control  ||| S:2554 E:2562 ||| NN
specimens  ||| S:2562 E:2572 ||| NNS
( ||| S:2572 E:2573 ||| -LRB-
Figure  ||| S:2573 E:2580 ||| NNP
1Aand  ||| S:2580 E:2586 ||| NNP
1C ||| S:2586 E:2588 ||| NNP
) ||| S:2588 E:2589 ||| -RRB-
,  ||| S:2589 E:2591 ||| ,
but  ||| S:2591 E:2595 ||| CC
could  ||| S:2595 E:2601 ||| MD
not  ||| S:2601 E:2605 ||| RB
be  ||| S:2605 E:2616 ||| VB
identified  ||| S:2616 E:2627 ||| VBN
in  ||| S:2627 E:2630 ||| IN
specimens  ||| S:2630 E:2640 ||| NNS
from  ||| S:2640 E:2645 ||| IN
estradiol-treated  ||| S:2645 E:2663 ||| JJ
animals  ||| S:2663 E:2679 ||| NNS
( ||| S:2679 E:2680 ||| -LRB-
Figure  ||| S:2680 E:2687 ||| NNP
1B ||| S:2687 E:2689 ||| NNP
,  ||| S:2689 E:2691 ||| ,
1Dand  ||| S:2691 E:2697 ||| CD
1E ||| S:2697 E:2699 ||| CD
) ||| S:2699 E:2700 ||| -RRB-
.  ||| S:2700 E:2702 ||| .
These  ||| S:2702 E:2708 ||| DT
changes  ||| S:2708 E:2716 ||| NNS
were  ||| S:2716 E:2721 ||| VBD
not  ||| S:2721 E:2725 ||| RB
due  ||| S:2725 E:2729 ||| JJ
to  ||| S:2729 E:2740 ||| TO
differences  ||| S:2740 E:2752 ||| NNS
in  ||| S:2752 E:2755 ||| IN
radiographic  ||| S:2755 E:2768 ||| JJ
technique  ||| S:2768 E:2778 ||| NN
since  ||| S:2778 E:2784 ||| IN
control  ||| S:2784 E:2792 ||| NN
and  ||| S:2792 E:2804 ||| CC
estradiol-treated  ||| S:2804 E:2822 ||| JJ
femurs  ||| S:2822 E:2829 ||| NNS
shown  ||| S:2829 E:2835 ||| VBN
in  ||| S:2835 E:2838 ||| IN
Figure  ||| S:2838 E:2845 ||| NNP
1were  ||| S:2845 E:2851 ||| NNP
exposed  ||| S:2851 E:2867 ||| VBD
side-by-side  ||| S:2867 E:2880 ||| RB
on  ||| S:2880 E:2883 ||| IN
the  ||| S:2883 E:2887 ||| DT
same  ||| S:2887 E:2892 ||| JJ
film ||| S:2892 E:2896 ||| NN
.  ||| S:2896 E:2906 ||| .
Histologic  ||| S:2906 E:2917 ||| JJ
examination  ||| S:2917 E:2929 ||| NN
also  ||| S:2929 E:2934 ||| RB
confirmed  ||| S:2934 E:2944 ||| VBD
osteosclerotic  ||| S:2944 E:2967 ||| JJ
features  ||| S:2967 E:2976 ||| NNS
in  ||| S:2976 E:2979 ||| IN
femurs  ||| S:2979 E:2986 ||| NN
from  ||| S:2986 E:2991 ||| IN
estradiol-treated  ||| S:2991 E:3009 ||| JJ
mice ||| S:3009 E:3013 ||| NNS
.  ||| S:3013 E:3015 ||| .
Specimens  ||| S:3015 E:3033 ||| NNS
from  ||| S:3033 E:3038 ||| IN
estradiol-treated  ||| S:3038 E:3056 ||| JJ
mice  ||| S:3056 E:3061 ||| NNS
contained  ||| S:3061 E:3071 ||| VBD
only  ||| S:3071 E:3076 ||| RB
small  ||| S:3076 E:3082 ||| JJ
regions  ||| S:3082 E:3090 ||| NNS
of  ||| S:3090 E:3101 ||| IN
bone  ||| S:3101 E:3106 ||| NN
marrow  ||| S:3106 E:3113 ||| NNS
( ||| S:3113 E:3114 ||| -LRB-
Fig.  ||| S:3114 E:3119 ||| NNP
2B ||| S:3119 E:3121 ||| NNP
)  ||| S:3121 E:3123 ||| -RRB-
in  ||| S:3123 E:3126 ||| IN
contrast  ||| S:3126 E:3135 ||| NN
to  ||| S:3135 E:3138 ||| TO
control  ||| S:3138 E:3146 ||| VB
bones  ||| S:3146 E:3152 ||| NNS
( ||| S:3152 E:3153 ||| -LRB-
Figure  ||| S:3153 E:3168 ||| NNP
2A ||| S:3168 E:3170 ||| NNP
) ||| S:3170 E:3171 ||| -RRB-
.  ||| S:3171 E:3173 ||| .
Since  ||| S:3173 E:3179 ||| IN
the  ||| S:3179 E:3183 ||| DT
normal ||| S:3183 E:3189 ||| JJ
,  ||| S:3189 E:3191 ||| ,
pre-estradiol  ||| S:3191 E:3205 ||| JJ
treatment  ||| S:3205 E:3215 ||| NN
endosteal  ||| S:3215 E:3233 ||| NN
margin  ||| S:3233 E:3240 ||| NN
could  ||| S:3240 E:3246 ||| MD
still  ||| S:3246 E:3252 ||| RB
be  ||| S:3252 E:3255 ||| VB
histologically  ||| S:3255 E:3270 ||| VBN
identified  ||| S:3270 E:3281 ||| VBN
on  ||| S:3281 E:3284 ||| IN
these  ||| S:3284 E:3298 ||| DT
specimens ||| S:3298 E:3307 ||| NN
,  ||| S:3307 E:3309 ||| ,
specimens  ||| S:3309 E:3319 ||| NNS
were  ||| S:3319 E:3324 ||| VBD
evaluated  ||| S:3324 E:3334 ||| VBN
with  ||| S:3334 E:3339 ||| IN
quantitative  ||| S:3339 E:3360 ||| JJ
histomorphometry  ||| S:3360 E:3377 ||| NN
by  ||| S:3377 E:3380 ||| IN
first  ||| S:3380 E:3386 ||| JJ
measuring  ||| S:3386 E:3396 ||| VBG
the  ||| S:3396 E:3400 ||| DT
old ||| S:3400 E:3403 ||| JJ
,  ||| S:3403 E:3405 ||| ,
normal  ||| S:3405 E:3412 ||| JJ
marrow  ||| S:3412 E:3427 ||| JJ
area  ||| S:3427 E:3432 ||| NN
and  ||| S:3432 E:3436 ||| CC
then  ||| S:3436 E:3441 ||| RB
measuring  ||| S:3441 E:3451 ||| VBG
the  ||| S:3451 E:3455 ||| DT
small  ||| S:3455 E:3461 ||| JJ
marrow  ||| S:3461 E:3468 ||| JJ
cavity  ||| S:3468 E:3475 ||| JJ
areas  ||| S:3475 E:3489 ||| NNS
present  ||| S:3489 E:3497 ||| JJ
at  ||| S:3497 E:3500 ||| IN
time  ||| S:3500 E:3505 ||| NN
of  ||| S:3505 E:3508 ||| IN
harvest ||| S:3508 E:3515 ||| NN
.  ||| S:3515 E:3517 ||| .
On  ||| S:3517 E:3520 ||| IN
average  ||| S:3520 E:3528 ||| JJ
86 ||| S:3528 E:3530 ||| CD
%  ||| S:3530 E:3532 ||| NN
of  ||| S:3532 E:3535 ||| IN
mid-shaft  ||| S:3535 E:3553 ||| JJ
marrow  ||| S:3553 E:3560 ||| JJ
space  ||| S:3560 E:3566 ||| NN
was  ||| S:3566 E:3570 ||| VBD
replaced  ||| S:3570 E:3579 ||| VBN
by  ||| S:3579 E:3582 ||| IN
bone  ||| S:3582 E:3587 ||| NN
in  ||| S:3587 E:3590 ||| IN
estradiol-treated  ||| S:3590 E:3608 ||| JJ
mice  ||| S:3608 E:3621 ||| NNS
at  ||| S:3621 E:3624 ||| IN
8  ||| S:3624 E:3626 ||| CD
weeks  ||| S:3626 E:3632 ||| NNS
( ||| S:3632 E:3633 ||| -LRB-
p  ||| S:3633 E:3635 ||| FW
< ||| S:3635 E:3637 ||| SYM
0.0001  ||| S:3637 E:3644 ||| FW
control  ||| S:3644 E:3652 ||| FW
vs  ||| S:3652 E:3663 ||| FW
estradiol-treated ||| S:3663 E:3680 ||| FW
) ||| S:3680 E:3681 ||| -RRB-
.  ||| S:3681 E:3691 ||| .
Osteoclasts  ||| S:3691 E:3703 ||| NNP
( ||| S:3703 E:3704 ||| -LRB-
Ocl ||| S:3704 E:3707 ||| NNP
)  ||| S:3707 E:3709 ||| -RRB-
present  ||| S:3709 E:3717 ||| JJ
in  ||| S:3717 E:3720 ||| IN
both  ||| S:3720 E:3725 ||| DT
control  ||| S:3725 E:3733 ||| NN
and  ||| S:3733 E:3745 ||| CC
estradiol-treated  ||| S:3745 E:3763 ||| JJ
mice  ||| S:3763 E:3768 ||| NNS
showed  ||| S:3768 E:3775 ||| VBD
positive  ||| S:3775 E:3784 ||| JJ
localization  ||| S:3784 E:3797 ||| NN
of  ||| S:3797 E:3800 ||| IN
TRAP  ||| S:3800 E:3813 ||| NNP
( ||| S:3813 E:3814 ||| -LRB-
Figure  ||| S:3814 E:3821 ||| NNP
2C ||| S:3821 E:3823 ||| NNP
) ||| S:3823 E:3824 ||| -RRB-
.  ||| S:3824 E:3826 ||| .
In  ||| S:3826 E:3829 ||| IN
contrast  ||| S:3829 E:3838 ||| NN
to  ||| S:3838 E:3841 ||| TO
the  ||| S:3841 E:3845 ||| DT
close  ||| S:3845 E:3851 ||| JJ
apposition  ||| S:3851 E:3862 ||| NN
of  ||| S:3862 E:3865 ||| IN
Ocl  ||| S:3865 E:3869 ||| NNP
to  ||| S:3869 E:3880 ||| TO
the  ||| S:3880 E:3884 ||| DT
bone  ||| S:3884 E:3889 ||| NN
surface  ||| S:3889 E:3897 ||| NN
seen  ||| S:3897 E:3902 ||| VBN
in  ||| S:3902 E:3905 ||| IN
control  ||| S:3905 E:3913 ||| NN
specimens ||| S:3913 E:3922 ||| NNS
,  ||| S:3922 E:3924 ||| ,
in  ||| S:3924 E:3935 ||| IN
estradiol-treated  ||| S:3935 E:3953 ||| JJ
animals  ||| S:3953 E:3961 ||| NNS
Ocl  ||| S:3961 E:3965 ||| NNP
extended  ||| S:3965 E:3974 ||| VBD
away  ||| S:3974 E:3979 ||| RP
from  ||| S:3979 E:3984 ||| IN
the  ||| S:3984 E:3988 ||| DT
bone  ||| S:3988 E:4001 ||| NN
surface  ||| S:4001 E:4009 ||| NN
with  ||| S:4009 E:4014 ||| IN
little  ||| S:4014 E:4021 ||| JJ
bone  ||| S:4021 E:4026 ||| NN
contact  ||| S:4026 E:4034 ||| NN
( ||| S:4034 E:4035 ||| -LRB-
Figure  ||| S:4035 E:4042 ||| NNP
2D ||| S:4042 E:4044 ||| NNP
) ||| S:4044 E:4045 ||| -RRB-
.  ||| S:4045 E:4047 ||| .
In  ||| S:4047 E:4050 ||| IN
order  ||| S:4050 E:4056 ||| NN
to  ||| S:4056 E:4067 ||| TO
further  ||| S:4067 E:4075 ||| RB
investigate  ||| S:4075 E:4087 ||| VB
this  ||| S:4087 E:4092 ||| DT
observation ||| S:4092 E:4103 ||| NN
,  ||| S:4103 E:4105 ||| ,
transmission  ||| S:4105 E:4118 ||| JJ
electron  ||| S:4118 E:4135 ||| JJ
microscopy  ||| S:4135 E:4146 ||| NN
was  ||| S:4146 E:4150 ||| VBD
performed  ||| S:4150 E:4160 ||| VBN
to  ||| S:4160 E:4163 ||| TO
examine  ||| S:4163 E:4171 ||| VB
the  ||| S:4171 E:4175 ||| DT
fine  ||| S:4175 E:4180 ||| JJ
structure  ||| S:4180 E:4190 ||| NN
of  ||| S:4190 E:4201 ||| IN
the  ||| S:4201 E:4205 ||| DT
Ocl  ||| S:4205 E:4209 ||| NNP
in  ||| S:4209 E:4212 ||| IN
estradiol-treated  ||| S:4212 E:4230 ||| JJ
and  ||| S:4230 E:4234 ||| CC
control  ||| S:4234 E:4242 ||| NN
specimens ||| S:4242 E:4251 ||| NNS
.  ||| S:4251 E:4261 ||| .
Figure  ||| S:4261 E:4268 ||| NN
3Aillustrates  ||| S:4268 E:4282 ||| VBZ
the  ||| S:4282 E:4286 ||| DT
normal  ||| S:4286 E:4293 ||| JJ
ultrastructural  ||| S:4293 E:4317 ||| JJ
appearance  ||| S:4317 E:4328 ||| NN
of  ||| S:4328 E:4331 ||| IN
an  ||| S:4331 E:4334 ||| DT
Ocl  ||| S:4334 E:4338 ||| NNP
from  ||| S:4338 E:4343 ||| IN
a  ||| S:4343 E:4345 ||| DT
control  ||| S:4345 E:4353 ||| NN
femur ||| S:4353 E:4358 ||| NNS
;  ||| S:4358 E:4360 ||| :
note  ||| S:4360 E:4365 ||| VBP
the  ||| S:4365 E:4369 ||| DT
normal  ||| S:4369 E:4384 ||| JJ
ruffled  ||| S:4384 E:4392 ||| JJ
border  ||| S:4392 E:4399 ||| NN
and  ||| S:4399 E:4403 ||| CC
snug  ||| S:4403 E:4408 ||| JJ
apposition  ||| S:4408 E:4419 ||| NN
of  ||| S:4419 E:4422 ||| IN
the  ||| S:4422 E:4426 ||| DT
Ocl  ||| S:4426 E:4430 ||| NNP
to  ||| S:4430 E:4433 ||| TO
the  ||| S:4433 E:4437 ||| DT
bone  ||| S:4437 E:4450 ||| NN
surface ||| S:4450 E:4457 ||| NN
.  ||| S:4457 E:4459 ||| .
Ocl  ||| S:4459 E:4463 ||| NNP
from  ||| S:4463 E:4468 ||| IN
estradiol-treated  ||| S:4468 E:4486 ||| JJ
animals ||| S:4486 E:4493 ||| NNS
,  ||| S:4493 E:4495 ||| ,
however ||| S:4495 E:4502 ||| RB
,  ||| S:4502 E:4512 ||| ,
frequently  ||| S:4512 E:4523 ||| RB
showed  ||| S:4523 E:4530 ||| VBD
only  ||| S:4530 E:4535 ||| RB
one  ||| S:4535 E:4539 ||| CD
margin  ||| S:4539 E:4546 ||| NN
of  ||| S:4546 E:4549 ||| IN
the  ||| S:4549 E:4553 ||| DT
cell  ||| S:4553 E:4558 ||| NN
perimeter  ||| S:4558 E:4576 ||| VBZ
involved  ||| S:4576 E:4585 ||| VBN
with  ||| S:4585 E:4590 ||| IN
small  ||| S:4590 E:4596 ||| JJ
areas  ||| S:4596 E:4602 ||| NNS
of  ||| S:4602 E:4605 ||| IN
ruffed  ||| S:4605 E:4612 ||| JJ
border  ||| S:4612 E:4619 ||| NN
formation ||| S:4619 E:4628 ||| NN
,  ||| S:4628 E:4630 ||| ,
with  ||| S:4630 E:4643 ||| IN
the  ||| S:4643 E:4647 ||| DT
remainder  ||| S:4647 E:4657 ||| NN
of  ||| S:4657 E:4660 ||| IN
the  ||| S:4660 E:4664 ||| DT
cell  ||| S:4664 E:4669 ||| NN
surface  ||| S:4669 E:4677 ||| NN
displaying  ||| S:4677 E:4688 ||| VBG
a  ||| S:4688 E:4690 ||| DT
smooth  ||| S:4690 E:4705 ||| JJ
profile  ||| S:4705 E:4713 ||| NN
( ||| S:4713 E:4714 ||| -LRB-
Fig.  ||| S:4714 E:4719 ||| NNP
3B ||| S:4719 E:4721 ||| NNP
) ||| S:4721 E:4722 ||| -RRB-
.  ||| S:4722 E:4724 ||| .
Some  ||| S:4724 E:4729 ||| DT
Ocl  ||| S:4729 E:4733 ||| NNP
from  ||| S:4733 E:4738 ||| IN
estradiol-treated  ||| S:4738 E:4756 ||| JJ
animals  ||| S:4756 E:4772 ||| NNS
had  ||| S:4772 E:4776 ||| VBD
no  ||| S:4776 E:4779 ||| DT
ruffled  ||| S:4779 E:4787 ||| JJ
borders  ||| S:4787 E:4795 ||| NNS
in  ||| S:4795 E:4798 ||| IN
spite  ||| S:4798 E:4804 ||| NN
of  ||| S:4804 E:4807 ||| IN
the  ||| S:4807 E:4811 ||| DT
appearance  ||| S:4811 E:4822 ||| NN
of  ||| S:4822 E:4825 ||| IN
some  ||| S:4825 E:4838 ||| DT
attempt  ||| S:4838 E:4846 ||| NN
to  ||| S:4846 E:4849 ||| TO
form  ||| S:4849 E:4854 ||| VB
sealing  ||| S:4854 E:4862 ||| VBG
podosome  ||| S:4862 E:4871 ||| JJ
regions  ||| S:4871 E:4879 ||| NNS
( ||| S:4879 E:4880 ||| -LRB-
Fig.  ||| S:4880 E:4885 ||| NNP
3C ||| S:4885 E:4887 ||| NNP
) ||| S:4887 E:4888 ||| -RRB-
.  ||| S:4888 E:4912 ||| .
Discussion  ||| S:4912 E:4931 ||| NN
The  ||| S:4931 E:4935 ||| DT
present  ||| S:4935 E:4943 ||| JJ
study  ||| S:4943 E:4949 ||| NN
indicated  ||| S:4949 E:4959 ||| VBD
that  ||| S:4959 E:4964 ||| DT
severe  ||| S:4964 E:4971 ||| JJ
changes  ||| S:4971 E:4979 ||| NNS
in  ||| S:4979 E:4982 ||| IN
Ocl  ||| S:4982 E:4994 ||| NNP
morphology  ||| S:4994 E:5005 ||| NNS
are  ||| S:5005 E:5009 ||| VBP
associated  ||| S:5009 E:5020 ||| VBN
with  ||| S:5020 E:5025 ||| IN
the  ||| S:5025 E:5029 ||| DT
cells ||| S:5029 E:5034 ||| NNS
'  ||| S:5034 E:5036 ||| POS
inability  ||| S:5036 E:5046 ||| NN
to  ||| S:5046 E:5057 ||| TO
carry  ||| S:5057 E:5063 ||| VB
out  ||| S:5063 E:5067 ||| RP
resorption  ||| S:5067 E:5078 ||| NNS
in  ||| S:5078 E:5081 ||| IN
the  ||| S:5081 E:5085 ||| DT
osteosclerotic  ||| S:5085 E:5108 ||| JJ
estradiol-treated  ||| S:5108 E:5126 ||| JJ
mouse ||| S:5126 E:5131 ||| NN
.  ||| S:5131 E:5133 ||| .
Although  ||| S:5133 E:5142 ||| IN
osteoclasts  ||| S:5142 E:5154 ||| NN
retained  ||| S:5154 E:5163 ||| VBD
TRAP  ||| S:5163 E:5176 ||| NNP
activity ||| S:5176 E:5184 ||| NN
,  ||| S:5184 E:5186 ||| ,
ultrastructural  ||| S:5186 E:5202 ||| JJ
alterations  ||| S:5202 E:5214 ||| NN
were  ||| S:5214 E:5219 ||| VBD
identified  ||| S:5219 E:5230 ||| VBN
in  ||| S:5230 E:5241 ||| IN
estradiol-treated  ||| S:5241 E:5259 ||| JJ
animals  ||| S:5259 E:5267 ||| NNS
in  ||| S:5267 E:5270 ||| IN
both  ||| S:5270 E:5275 ||| PDT
the  ||| S:5275 E:5279 ||| DT
sealing  ||| S:5279 E:5287 ||| JJ
patterns  ||| S:5287 E:5296 ||| NNS
of  ||| S:5296 E:5307 ||| IN
osteoclasts  ||| S:5307 E:5319 ||| NN
against  ||| S:5319 E:5327 ||| IN
the  ||| S:5327 E:5331 ||| DT
bone  ||| S:5331 E:5336 ||| NN
surface  ||| S:5336 E:5344 ||| NN
and  ||| S:5344 E:5348 ||| CC
in  ||| S:5348 E:5351 ||| IN
altered  ||| S:5351 E:5359 ||| JJ
brush  ||| S:5359 E:5373 ||| NN
border  ||| S:5373 E:5380 ||| NN
morphology ||| S:5380 E:5390 ||| NN
.  ||| S:5390 E:5392 ||| .
Proper  ||| S:5392 E:5399 ||| JJ
sealing  ||| S:5399 E:5407 ||| NN
of  ||| S:5407 E:5410 ||| IN
the  ||| S:5410 E:5414 ||| DT
osteoclast  ||| S:5414 E:5425 ||| NN
against  ||| S:5425 E:5441 ||| IN
the  ||| S:5441 E:5445 ||| DT
bone  ||| S:5445 E:5450 ||| NN
surface  ||| S:5450 E:5458 ||| NN
and  ||| S:5458 E:5462 ||| CC
a  ||| S:5462 E:5464 ||| DT
functional  ||| S:5464 E:5475 ||| JJ
brush  ||| S:5475 E:5481 ||| NN
border  ||| S:5481 E:5488 ||| NN
are  ||| S:5488 E:5492 ||| VBP
two  ||| S:5492 E:5504 ||| CD
ultrastructural  ||| S:5504 E:5520 ||| CD
components  ||| S:5520 E:5531 ||| NNS
believed  ||| S:5531 E:5540 ||| VBD
to  ||| S:5540 E:5543 ||| TO
be  ||| S:5543 E:5546 ||| VB
of  ||| S:5546 E:5549 ||| IN
major  ||| S:5549 E:5563 ||| JJ
importance  ||| S:5563 E:5574 ||| NN
in  ||| S:5574 E:5577 ||| IN
Ocl  ||| S:5577 E:5581 ||| NNP
function ||| S:5581 E:5589 ||| NN
.  ||| S:5589 E:5591 ||| .
The  ||| S:5591 E:5595 ||| DT
ultrastructural  ||| S:5595 E:5611 ||| JJ
alterations  ||| S:5611 E:5631 ||| NNS
identified  ||| S:5631 E:5642 ||| VBN
in  ||| S:5642 E:5645 ||| IN
estrogen-treated  ||| S:5645 E:5662 ||| JJ
mice  ||| S:5662 E:5667 ||| NNS
were  ||| S:5667 E:5672 ||| VBD
very  ||| S:5672 E:5677 ||| RB
likely  ||| S:5677 E:5684 ||| RB
the  ||| S:5684 E:5696 ||| DT
cellular  ||| S:5696 E:5705 ||| JJ
functional  ||| S:5705 E:5716 ||| JJ
basis  ||| S:5716 E:5722 ||| NN
for  ||| S:5722 E:5726 ||| IN
the  ||| S:5726 E:5730 ||| DT
decreased  ||| S:5730 E:5740 ||| JJ
resorption  ||| S:5740 E:5751 ||| NN
and  ||| S:5751 E:5763 ||| CC
development  ||| S:5763 E:5775 ||| NN
of  ||| S:5775 E:5778 ||| IN
osteosclerosis  ||| S:5778 E:5793 ||| NN
in  ||| S:5793 E:5796 ||| IN
estrogen-treated  ||| S:5796 E:5813 ||| JJ
mice ||| S:5813 E:5817 ||| NNS
.  ||| S:5817 E:5827 ||| .
Osteoclast  ||| S:5827 E:5838 ||| JJ
function  ||| S:5838 E:5847 ||| NN
and  ||| S:5847 E:5851 ||| CC
ultrastructural  ||| S:5851 E:5867 ||| JJ
morphology  ||| S:5867 E:5878 ||| NNS
have  ||| S:5878 E:5891 ||| VBP
been  ||| S:5891 E:5896 ||| VBN
shown  ||| S:5896 E:5902 ||| VBN
to  ||| S:5902 E:5905 ||| TO
be  ||| S:5905 E:5908 ||| VB
highly  ||| S:5908 E:5915 ||| RB
responsive  ||| S:5915 E:5926 ||| JJ
to  ||| S:5926 E:5929 ||| TO
anti-resorbing  ||| S:5929 E:5944 ||| JJ
agents  ||| S:5944 E:5959 ||| NNS
such  ||| S:5959 E:5964 ||| JJ
as  ||| S:5964 E:5967 ||| IN
ethane-1-hydroxy-1,1-diphosphonate  ||| S:5967 E:6002 ||| NNP
( ||| S:6002 E:6003 ||| -LRB-
EHDP ||| S:6003 E:6007 ||| NNP
)  ||| S:6007 E:6009 ||| -RRB-
[  ||| S:6009 E:6011 ||| -LRB-
8 ||| S:6011 E:6012 ||| CD
,  ||| S:6012 E:6014 ||| ,
9 ||| S:6014 E:6015 ||| CD
] ||| S:6015 E:6016 ||| -RRB-
,  ||| S:6016 E:6026 ||| ,
dichloromethylene  ||| S:6026 E:6044 ||| FW
diphosphanate  ||| S:6044 E:6058 ||| FW
( ||| S:6058 E:6059 ||| -LRB-
Cl  ||| S:6059 E:6071 ||| NNP
2  ||| S:6071 E:6073 ||| CD
MDP ||| S:6073 E:6076 ||| NNP
)  ||| S:6076 E:6078 ||| -RRB-
[  ||| S:6078 E:6080 ||| -LRB-
10 ||| S:6080 E:6082 ||| CD
] ||| S:6082 E:6083 ||| -RRB-
,  ||| S:6083 E:6085 ||| ,
calcitonin  ||| S:6085 E:6096 ||| NNS
[  ||| S:6096 E:6098 ||| -LRB-
11 ||| S:6098 E:6100 ||| CD
,  ||| S:6100 E:6102 ||| ,
12 ||| S:6102 E:6104 ||| CD
,  ||| S:6104 E:6106 ||| ,
13 ||| S:6106 E:6108 ||| CD
] ||| S:6108 E:6109 ||| -RRB-
,  ||| S:6109 E:6119 ||| ,
other  ||| S:6119 E:6125 ||| JJ
anti-resorptive  ||| S:6125 E:6141 ||| JJ
agents ||| S:6141 E:6147 ||| NNS
,  ||| S:6147 E:6149 ||| ,
such  ||| S:6149 E:6154 ||| JJ
as  ||| S:6154 E:6157 ||| IN
mithramycin  ||| S:6157 E:6169 ||| NNS
[  ||| S:6169 E:6171 ||| -LRB-
14 ||| S:6171 E:6173 ||| CD
] ||| S:6173 E:6174 ||| -RRB-
,  ||| S:6174 E:6184 ||| ,
and  ||| S:6184 E:6188 ||| CC
to  ||| S:6188 E:6191 ||| TO
gallium  ||| S:6191 E:6199 ||| VB
nitrate  ||| S:6199 E:6207 ||| NNS
[  ||| S:6207 E:6209 ||| -LRB-
15 ||| S:6209 E:6211 ||| CD
] ||| S:6211 E:6212 ||| -RRB-
.  ||| S:6212 E:6222 ||| .
Although  ||| S:6222 E:6231 ||| IN
histochemical  ||| S:6231 E:6245 ||| FW
TRAP  ||| S:6245 E:6250 ||| FW
localization  ||| S:6250 E:6263 ||| FW
provides  ||| S:6263 E:6272 ||| VBZ
an  ||| S:6272 E:6283 ||| DT
accurate  ||| S:6283 E:6292 ||| JJ
and  ||| S:6292 E:6296 ||| CC
sensitive  ||| S:6296 E:6306 ||| JJ
histologic  ||| S:6306 E:6317 ||| JJ
method  ||| S:6317 E:6324 ||| NN
for  ||| S:6324 E:6328 ||| IN
identification  ||| S:6328 E:6351 ||| NN
of  ||| S:6351 E:6354 ||| IN
Ocl ||| S:6354 E:6357 ||| NNP
,  ||| S:6357 E:6359 ||| ,
understanding  ||| S:6359 E:6373 ||| VBG
osteoclastogenesis  ||| S:6373 E:6392 ||| NNS
and  ||| S:6392 E:6396 ||| CC
Ocl  ||| S:6396 E:6400 ||| NNP
function  ||| S:6400 E:6417 ||| NN
remain  ||| S:6417 E:6424 ||| VBP
a  ||| S:6424 E:6426 ||| DT
challenging  ||| S:6426 E:6438 ||| JJ
area  ||| S:6438 E:6443 ||| NN
of  ||| S:6443 E:6446 ||| IN
bone  ||| S:6446 E:6451 ||| NN
research ||| S:6451 E:6459 ||| NN
.  ||| S:6459 E:6461 ||| .
The  ||| S:6461 E:6465 ||| DT
current  ||| S:6465 E:6481 ||| JJ
understanding  ||| S:6481 E:6495 ||| NN
of  ||| S:6495 E:6498 ||| IN
Ocl  ||| S:6498 E:6502 ||| NNP
function  ||| S:6502 E:6511 ||| NN
is  ||| S:6511 E:6514 ||| VBZ
that  ||| S:6514 E:6519 ||| IN
the  ||| S:6519 E:6523 ||| DT
Ocl  ||| S:6523 E:6527 ||| NNP
seals  ||| S:6527 E:6533 ||| VBD
its  ||| S:6533 E:6545 ||| PRP$
perimeter  ||| S:6545 E:6555 ||| NN
along  ||| S:6555 E:6561 ||| IN
the  ||| S:6561 E:6565 ||| DT
bone  ||| S:6565 E:6570 ||| NN
surface  ||| S:6570 E:6578 ||| NN
by  ||| S:6578 E:6581 ||| IN
means  ||| S:6581 E:6587 ||| NNS
of  ||| S:6587 E:6590 ||| IN
the  ||| S:6590 E:6594 ||| DT
podosome  ||| S:6594 E:6603 ||| NN
[  ||| S:6603 E:6613 ||| -LRB-
16 ||| S:6613 E:6615 ||| CD
,  ||| S:6615 E:6617 ||| ,
17 ||| S:6617 E:6619 ||| CD
,  ||| S:6619 E:6621 ||| ,
18 ||| S:6621 E:6623 ||| CD
]  ||| S:6623 E:6625 ||| -RRB-
.  ||| S:6625 E:6627 ||| .
Within  ||| S:6627 E:6634 ||| IN
this  ||| S:6634 E:6639 ||| DT
sealed  ||| S:6639 E:6646 ||| JJ
margin ||| S:6646 E:6652 ||| NN
,  ||| S:6652 E:6654 ||| ,
projections  ||| S:6654 E:6666 ||| NNS
from  ||| S:6666 E:6679 ||| IN
the  ||| S:6679 E:6683 ||| DT
cytoplasm  ||| S:6683 E:6693 ||| JJ
form  ||| S:6693 E:6698 ||| NN
the  ||| S:6698 E:6702 ||| DT
ruffled  ||| S:6702 E:6710 ||| JJ
border ||| S:6710 E:6716 ||| NN
,  ||| S:6716 E:6718 ||| ,
a  ||| S:6718 E:6720 ||| DT
specialized  ||| S:6720 E:6740 ||| JJ
Ocl-extracellular  ||| S:6740 E:6758 ||| JJ
space  ||| S:6758 E:6764 ||| NN
in  ||| S:6764 E:6767 ||| IN
which  ||| S:6767 E:6773 ||| WDT
bone  ||| S:6773 E:6778 ||| VBZ
resorption  ||| S:6778 E:6789 ||| JJ
occurs ||| S:6789 E:6795 ||| NN
.  ||| S:6795 E:6797 ||| .
In  ||| S:6797 E:6808 ||| IN
the  ||| S:6808 E:6812 ||| DT
present  ||| S:6812 E:6820 ||| JJ
study  ||| S:6820 E:6826 ||| NN
in  ||| S:6826 E:6829 ||| IN
the  ||| S:6829 E:6833 ||| DT
mouse ||| S:6833 E:6838 ||| NN
,  ||| S:6838 E:6840 ||| ,
differentiation  ||| S:6840 E:6856 ||| VBG
of  ||| S:6856 E:6867 ||| IN
osteoclast  ||| S:6867 E:6878 ||| JJ
progenitors  ||| S:6878 E:6890 ||| NN
appears  ||| S:6890 E:6898 ||| VBZ
to  ||| S:6898 E:6901 ||| TO
be  ||| S:6901 E:6904 ||| VB
dependent  ||| S:6904 E:6914 ||| JJ
on  ||| S:6914 E:6917 ||| IN
the  ||| S:6917 E:6929 ||| DT
direct  ||| S:6929 E:6936 ||| JJ
interaction  ||| S:6936 E:6948 ||| NN
of  ||| S:6948 E:6951 ||| IN
bone  ||| S:6951 E:6956 ||| NN
marrow  ||| S:6956 E:6963 ||| NN
stromal  ||| S:6963 E:6971 ||| NN
cells  ||| S:6971 E:6977 ||| NNS
with  ||| S:6977 E:6982 ||| IN
Ocl  ||| S:6982 E:6994 ||| NNP
precursor  ||| S:6994 E:7004 ||| NN
cells  ||| S:7004 E:7010 ||| NNS
[  ||| S:7010 E:7012 ||| -LRB-
19 ||| S:7012 E:7014 ||| CD
,  ||| S:7014 E:7016 ||| ,
20 ||| S:7016 E:7018 ||| CD
] ||| S:7018 E:7019 ||| -RRB-
.  ||| S:7019 E:7021 ||| .
Recent  ||| S:7021 E:7028 ||| JJ
data  ||| S:7028 E:7033 ||| NNS
of  ||| S:7033 E:7036 ||| IN
Baylink  ||| S:7036 E:7044 ||| NNP
[  ||| S:7044 E:7046 ||| -LRB-
21 ||| S:7046 E:7048 ||| CD
]  ||| S:7048 E:7050 ||| -RRB-
and  ||| S:7050 E:7062 ||| CC
Linkhart  ||| S:7062 E:7071 ||| NNP
[  ||| S:7071 E:7073 ||| -LRB-
22 ||| S:7073 E:7075 ||| CD
]  ||| S:7075 E:7077 ||| -RRB-
provide  ||| S:7077 E:7085 ||| VB
evidence  ||| S:7085 E:7094 ||| NN
that  ||| S:7094 E:7099 ||| IN
two  ||| S:7099 E:7103 ||| CD
inbred  ||| S:7103 E:7110 ||| CD
strains  ||| S:7110 E:7118 ||| NNS
of  ||| S:7118 E:7129 ||| IN
mice  ||| S:7129 E:7134 ||| NNS
with  ||| S:7134 E:7139 ||| IN
different  ||| S:7139 E:7149 ||| JJ
bone  ||| S:7149 E:7154 ||| NN
densities  ||| S:7154 E:7164 ||| NNS
may  ||| S:7164 E:7168 ||| MD
have  ||| S:7168 E:7173 ||| VB
fundamental  ||| S:7173 E:7193 ||| JJ
differences  ||| S:7193 E:7205 ||| NNS
in  ||| S:7205 E:7208 ||| IN
bone  ||| S:7208 E:7213 ||| NN
resorption  ||| S:7213 E:7224 ||| NNS
( ||| S:7224 E:7225 ||| -LRB-
not  ||| S:7225 E:7229 ||| RB
bone  ||| S:7229 E:7234 ||| JJ
formation ||| S:7234 E:7243 ||| NN
) ||| S:7243 E:7244 ||| -RRB-
,  ||| S:7244 E:7246 ||| ,
and  ||| S:7246 E:7258 ||| CC
that  ||| S:7258 E:7263 ||| IN
genes  ||| S:7263 E:7269 ||| NNS
affecting  ||| S:7269 E:7279 ||| VBG
the  ||| S:7279 E:7283 ||| DT
bone  ||| S:7283 E:7288 ||| FW
marrow  ||| S:7288 E:7295 ||| FW
Ocl  ||| S:7295 E:7299 ||| FW
precursor  ||| S:7299 E:7317 ||| FW
population  ||| S:7317 E:7328 ||| NN
may  ||| S:7328 E:7332 ||| MD
contribute  ||| S:7332 E:7343 ||| VB
to  ||| S:7343 E:7346 ||| TO
relative  ||| S:7346 E:7355 ||| JJ
differences  ||| S:7355 E:7367 ||| NNS
in  ||| S:7367 E:7370 ||| IN
the  ||| S:7370 E:7382 ||| DT
C57BL ||| S:7382 E:7387 ||| NNP
/ ||| S:7387 E:7388 ||| NNP
6J  ||| S:7388 E:7391 ||| NNP
and  ||| S:7391 E:7395 ||| CC
C3H ||| S:7395 E:7398 ||| CD
/ ||| S:7398 E:7399 ||| CD
HeJ  ||| S:7399 E:7403 ||| JJ
strains ||| S:7403 E:7410 ||| NNS
.  ||| S:7410 E:7412 ||| .
In  ||| S:7412 E:7415 ||| IN
vivo  ||| S:7415 E:7420 ||| NN
and  ||| S:7420 E:7424 ||| CC
in  ||| S:7424 E:7427 ||| IN
vitro  ||| S:7427 E:7433 ||| JJ
studies  ||| S:7433 E:7449 ||| NNS
of  ||| S:7449 E:7452 ||| IN
avian  ||| S:7452 E:7458 ||| FW
osteoclasts  ||| S:7458 E:7470 ||| FW
led  ||| S:7470 E:7474 ||| FW
Pederson  ||| S:7474 E:7483 ||| FW
et  ||| S:7483 E:7486 ||| FW
al  ||| S:7486 E:7489 ||| FW
to  ||| S:7489 E:7492 ||| TO
suggest  ||| S:7492 E:7500 ||| VB
that  ||| S:7500 E:7513 ||| DT
modulation  ||| S:7513 E:7524 ||| NN
of  ||| S:7524 E:7527 ||| IN
the  ||| S:7527 E:7531 ||| DT
Ocl  ||| S:7531 E:7535 ||| JJ
response  ||| S:7535 E:7544 ||| NN
to  ||| S:7544 E:7547 ||| TO
estrogen  ||| S:7547 E:7556 ||| NNS
may  ||| S:7556 E:7560 ||| MD
be  ||| S:7560 E:7571 ||| VB
controlled  ||| S:7571 E:7582 ||| VBN
by  ||| S:7582 E:7585 ||| IN
alterations  ||| S:7585 E:7597 ||| NN
in  ||| S:7597 E:7600 ||| IN
the  ||| S:7600 E:7604 ||| DT
Ocl  ||| S:7604 E:7608 ||| JJ
estrogen  ||| S:7608 E:7617 ||| JJ
receptor  ||| S:7617 E:7634 ||| NN
level  ||| S:7634 E:7640 ||| NN
[  ||| S:7640 E:7642 ||| -LRB-
3 ||| S:7642 E:7643 ||| LS
] ||| S:7643 E:7644 ||| -RRB-
.  ||| S:7644 E:7654 ||| .
Maturation  ||| S:7654 E:7665 ||| NNP
of  ||| S:7665 E:7668 ||| IN
osteoclasts  ||| S:7668 E:7680 ||| NN
from  ||| S:7680 E:7685 ||| IN
their  ||| S:7685 E:7691 ||| PRP$
macrophage  ||| S:7691 E:7710 ||| JJ
precursors  ||| S:7710 E:7721 ||| NN
requires  ||| S:7721 E:7730 ||| VBZ
marrow  ||| S:7730 E:7737 ||| JJ
stromal  ||| S:7737 E:7745 ||| JJ
cells  ||| S:7745 E:7751 ||| NNS
or  ||| S:7751 E:7754 ||| CC
their  ||| S:7754 E:7768 ||| PRP$
osteoblast  ||| S:7768 E:7779 ||| JJ
progeny  ||| S:7779 E:7787 ||| NN
as  ||| S:7787 E:7790 ||| IN
shown  ||| S:7790 E:7796 ||| VBN
by  ||| S:7796 E:7799 ||| IN
Udagawa  ||| S:7799 E:7807 ||| NNP
et  ||| S:7807 E:7810 ||| FW
al  ||| S:7810 E:7813 ||| FW
[  ||| S:7813 E:7815 ||| -LRB-
23 ||| S:7815 E:7817 ||| CD
] ||| S:7817 E:7818 ||| -RRB-
.  ||| S:7818 E:7820 ||| .
These  ||| S:7820 E:7834 ||| DT
cells  ||| S:7834 E:7840 ||| NNS
produce  ||| S:7840 E:7848 ||| VBP
macrophage  ||| S:7848 E:7859 ||| JJ
colony-stimulating  ||| S:7859 E:7878 ||| JJ
factor  ||| S:7878 E:7885 ||| NN
( ||| S:7885 E:7886 ||| -LRB-
M-CSF ||| S:7886 E:7891 ||| NNP
)  ||| S:7891 E:7901 ||| -RRB-
and  ||| S:7901 E:7905 ||| CC
the  ||| S:7905 E:7909 ||| DT
receptor  ||| S:7909 E:7918 ||| NN
for  ||| S:7918 E:7922 ||| IN
activation  ||| S:7922 E:7933 ||| NN
of  ||| S:7933 E:7936 ||| IN
nuclear  ||| S:7936 E:7944 ||| JJ
factor  ||| S:7944 E:7951 ||| NN
kappa  ||| S:7951 E:7957 ||| NN
b  ||| S:7957 E:7967 ||| NNS
( ||| S:7967 E:7968 ||| -LRB-
NF-  ||| S:7968 E:7981 ||| FW
k  ||| S:7981 E:7983 ||| FW
B ||| S:7983 E:7984 ||| NNP
)  ||| S:7984 E:7986 ||| -RRB-
( ||| S:7986 E:7987 ||| -LRB-
RANK ||| S:7987 E:7991 ||| NNP
)  ||| S:7991 E:7993 ||| -RRB-
ligand  ||| S:7993 E:8000 ||| NNS
( ||| S:8000 E:8001 ||| -LRB-
RANKL ||| S:8001 E:8006 ||| NNP
) ||| S:8006 E:8007 ||| -RRB-
.  ||| S:8007 E:8009 ||| .
M-CSF  ||| S:8009 E:8015 ||| NNP
is  ||| S:8015 E:8026 ||| VBZ
essential  ||| S:8026 E:8036 ||| JJ
for  ||| S:8036 E:8040 ||| IN
macrophage  ||| S:8040 E:8051 ||| JJ
maturation ||| S:8051 E:8061 ||| NN
,  ||| S:8061 E:8063 ||| ,
but  ||| S:8063 E:8067 ||| CC
formation  ||| S:8067 E:8077 ||| NN
of  ||| S:8077 E:8088 ||| IN
osteoclasts  ||| S:8088 E:8100 ||| VBG
also  ||| S:8100 E:8105 ||| RB
requires  ||| S:8105 E:8114 ||| VBZ
contact  ||| S:8114 E:8122 ||| NN
between  ||| S:8122 E:8130 ||| IN
osteoclast  ||| S:8130 E:8149 ||| JJ
precursors  ||| S:8149 E:8160 ||| NN
and  ||| S:8160 E:8164 ||| CC
stromal  ||| S:8164 E:8172 ||| JJ
cells  ||| S:8172 E:8178 ||| NNS
or  ||| S:8178 E:8181 ||| CC
osteoblasts  ||| S:8181 E:8193 ||| NNS
[  ||| S:8193 E:8195 ||| -LRB-
23 ||| S:8195 E:8197 ||| CD
] ||| S:8197 E:8198 ||| -RRB-
.  ||| S:8198 E:8200 ||| .
As  ||| S:8200 E:8211 ||| RB
described  ||| S:8211 E:8221 ||| VBN
by  ||| S:8221 E:8224 ||| IN
Hofbauer  ||| S:8224 E:8233 ||| NNP
et  ||| S:8233 E:8236 ||| FW
al  ||| S:8236 E:8239 ||| FW
[  ||| S:8239 E:8241 ||| -LRB-
24 ||| S:8241 E:8243 ||| CD
] ||| S:8243 E:8244 ||| -RRB-
,  ||| S:8244 E:8246 ||| ,
the  ||| S:8246 E:8250 ||| DT
quantity  ||| S:8250 E:8259 ||| NN
of  ||| S:8259 E:8262 ||| IN
bone  ||| S:8262 E:8275 ||| NN
resorbed  ||| S:8275 E:8284 ||| NN
depends  ||| S:8284 E:8292 ||| VBZ
on  ||| S:8292 E:8295 ||| IN
the  ||| S:8295 E:8299 ||| DT
balance  ||| S:8299 E:8307 ||| NN
between  ||| S:8307 E:8315 ||| IN
expression  ||| S:8315 E:8326 ||| NN
of  ||| S:8326 E:8329 ||| IN
RANKL  ||| S:8329 E:8343 ||| NNP
and  ||| S:8343 E:8347 ||| CC
of  ||| S:8347 E:8350 ||| IN
its  ||| S:8350 E:8354 ||| PRP$
inhibitor ||| S:8354 E:8363 ||| NN
,  ||| S:8363 E:8365 ||| ,
osteoprotegerin  ||| S:8365 E:8381 ||| NNS
( ||| S:8381 E:8382 ||| -LRB-
OPG ||| S:8382 E:8385 ||| NNP
) ||| S:8385 E:8386 ||| -RRB-
.  ||| S:8386 E:8388 ||| .
Hofbauer  ||| S:8388 E:8397 ||| FW
et  ||| S:8397 E:8400 ||| FW
al  ||| S:8400 E:8411 ||| FW
suggest  ||| S:8411 E:8419 ||| VBP
that  ||| S:8419 E:8424 ||| IN
the  ||| S:8424 E:8428 ||| DT
stimulation  ||| S:8428 E:8440 ||| NN
of  ||| S:8440 E:8443 ||| IN
the  ||| S:8443 E:8447 ||| DT
pool  ||| S:8447 E:8452 ||| NN
of  ||| S:8452 E:8455 ||| IN
M-CSF  ||| S:8455 E:8469 ||| JJ
precursors  ||| S:8469 E:8480 ||| NN
to  ||| S:8480 E:8483 ||| TO
committed  ||| S:8483 E:8493 ||| JJ
osteoclastogenesis  ||| S:8493 E:8512 ||| NN
by  ||| S:8512 E:8515 ||| IN
RANKL  ||| S:8515 E:8521 ||| NNP
may  ||| S:8521 E:8525 ||| MD
be  ||| S:8525 E:8536 ||| VB
one  ||| S:8536 E:8540 ||| CD
of  ||| S:8540 E:8543 ||| IN
the  ||| S:8543 E:8547 ||| DT
central  ||| S:8547 E:8555 ||| JJ
pathophysiologic  ||| S:8555 E:8572 ||| NNS
pathways  ||| S:8572 E:8581 ||| VBP
involved  ||| S:8581 E:8590 ||| VBN
in  ||| S:8590 E:8601 ||| IN
increasing  ||| S:8601 E:8612 ||| VBG
the  ||| S:8612 E:8616 ||| DT
number  ||| S:8616 E:8623 ||| NN
of  ||| S:8623 E:8626 ||| IN
osteoclasts  ||| S:8626 E:8638 ||| NN
in  ||| S:8638 E:8641 ||| IN
osteoporosis ||| S:8641 E:8653 ||| NN
.  ||| S:8653 E:8663 ||| .
Futures  ||| S:8663 E:8671 ||| NNS
studies  ||| S:8671 E:8679 ||| NNS
of  ||| S:8679 E:8682 ||| IN
the  ||| S:8682 E:8686 ||| DT
estrogen-treated  ||| S:8686 E:8703 ||| JJ
mouse  ||| S:8703 E:8709 ||| NN
model  ||| S:8709 E:8715 ||| NN
are  ||| S:8715 E:8727 ||| VBP
needed  ||| S:8727 E:8734 ||| VBN
which  ||| S:8734 E:8740 ||| WDT
are  ||| S:8740 E:8744 ||| VBP
designed  ||| S:8744 E:8753 ||| VBN
to  ||| S:8753 E:8756 ||| TO
address  ||| S:8756 E:8764 ||| VB
osteoclastogenesis  ||| S:8764 E:8783 ||| NNS
and  ||| S:8783 E:8795 ||| CC
osteoprotegerin  ||| S:8795 E:8811 ||| NNS
( ||| S:8811 E:8812 ||| -LRB-
OPG ||| S:8812 E:8815 ||| NNP
)  ||| S:8815 E:8817 ||| -RRB-
secretion  ||| S:8817 E:8827 ||| NN
by  ||| S:8827 E:8830 ||| IN
osteoblasts ||| S:8830 E:8841 ||| NN
.  ||| S:8841 E:8843 ||| .
OPG  ||| S:8843 E:8847 ||| NNP
is  ||| S:8847 E:8858 ||| VBZ
currently  ||| S:8858 E:8868 ||| RB
hypothesized  ||| S:8868 E:8881 ||| VBN
to  ||| S:8881 E:8884 ||| TO
be  ||| S:8884 E:8887 ||| VB
an  ||| S:8887 E:8890 ||| DT
important  ||| S:8890 E:8900 ||| JJ
paracrine  ||| S:8900 E:8918 ||| JJ
mediator  ||| S:8918 E:8927 ||| NN
of  ||| S:8927 E:8930 ||| IN
the  ||| S:8930 E:8934 ||| DT
antiresorptive  ||| S:8934 E:8949 ||| JJ
action  ||| S:8949 E:8956 ||| NN
of  ||| S:8956 E:8959 ||| IN
estrogen  ||| S:8959 E:8968 ||| NN
on  ||| S:8968 E:8971 ||| IN
bone  ||| S:8971 E:8984 ||| NN
cells  ||| S:8984 E:8990 ||| NNS
[  ||| S:8990 E:8992 ||| -LRB-
25 ||| S:8992 E:8994 ||| CD
] ||| S:8994 E:8995 ||| -RRB-
.  ||| S:8995 E:8997 ||| .
In  ||| S:8997 E:9000 ||| IN
osteoblast  ||| S:9000 E:9011 ||| JJ
cell  ||| S:9011 E:9016 ||| NN
lines  ||| S:9016 E:9022 ||| NNS
exposed  ||| S:9022 E:9030 ||| VBN
to  ||| S:9030 E:9033 ||| TO
estrogen ||| S:9033 E:9041 ||| VB
,  ||| S:9041 E:9051 ||| ,
OPG  ||| S:9051 E:9055 ||| NNP
mRNA  ||| S:9055 E:9060 ||| NNP
and  ||| S:9060 E:9064 ||| CC
protein  ||| S:9064 E:9072 ||| NN
levels  ||| S:9072 E:9079 ||| NNS
were  ||| S:9079 E:9084 ||| VBD
increased  ||| S:9084 E:9094 ||| VBN
compared  ||| S:9094 E:9103 ||| VBN
to  ||| S:9103 E:9114 ||| TO
controls ||| S:9114 E:9122 ||| NNS
.  ||| S:9122 E:9124 ||| .
Hofbauer  ||| S:9124 E:9133 ||| FW
et  ||| S:9133 E:9136 ||| FW
al  ||| S:9136 E:9139 ||| FW
have  ||| S:9139 E:9144 ||| VBP
suggested  ||| S:9144 E:9154 ||| VBN
that  ||| S:9154 E:9159 ||| IN
estrogen  ||| S:9159 E:9168 ||| NNS
may  ||| S:9168 E:9180 ||| MD
exert  ||| S:9180 E:9186 ||| VB
its  ||| S:9186 E:9190 ||| PRP$
anti-resorptive  ||| S:9190 E:9206 ||| JJ
effects  ||| S:9206 E:9214 ||| NNS
by  ||| S:9214 E:9217 ||| IN
enhancement  ||| S:9217 E:9229 ||| NN
of  ||| S:9229 E:9232 ||| IN
OPG  ||| S:9232 E:9244 ||| NNP
secretion  ||| S:9244 E:9254 ||| NN
by  ||| S:9254 E:9257 ||| IN
osteoblasts  ||| S:9257 E:9269 ||| NNS
[  ||| S:9269 E:9271 ||| -LRB-
11 ||| S:9271 E:9273 ||| CD
] ||| S:9273 E:9274 ||| -RRB-
.  ||| S:9274 E:9284 ||| .
Future  ||| S:9284 E:9291 ||| JJ
studies  ||| S:9291 E:9299 ||| NNS
should  ||| S:9299 E:9306 ||| MD
also  ||| S:9306 E:9311 ||| RB
assess  ||| S:9311 E:9318 ||| VB
the  ||| S:9318 E:9322 ||| DT
temporal  ||| S:9322 E:9339 ||| JJ
development  ||| S:9339 E:9351 ||| NN
of  ||| S:9351 E:9354 ||| IN
functional  ||| S:9354 E:9365 ||| JJ
changes  ||| S:9365 E:9373 ||| NNS
in  ||| S:9373 E:9376 ||| IN
the  ||| S:9376 E:9380 ||| DT
osteoclast  ||| S:9380 E:9399 ||| JJ
populations  ||| S:9399 E:9411 ||| NNS
during  ||| S:9411 E:9418 ||| IN
estrogen  ||| S:9418 E:9427 ||| JJ
treatment ||| S:9427 E:9436 ||| NN
,  ||| S:9436 E:9438 ||| ,
and  ||| S:9438 E:9442 ||| CC
the  ||| S:9442 E:9446 ||| DT
patterns  ||| S:9446 E:9455 ||| NNS
of  ||| S:9455 E:9466 ||| IN
osteoclast  ||| S:9466 E:9477 ||| JJ
death  ||| S:9477 E:9483 ||| NN
with  ||| S:9483 E:9488 ||| IN
special  ||| S:9488 E:9496 ||| JJ
attention  ||| S:9496 E:9506 ||| NN
to  ||| S:9506 E:9509 ||| TO
apoptosis ||| S:9509 E:9518 ||| VB
.  ||| S:9518 E:9528 ||| .
Estradiol  ||| S:9528 E:9538 ||| NNP
has  ||| S:9538 E:9542 ||| VBZ
been  ||| S:9542 E:9547 ||| VBN
shown  ||| S:9547 E:9553 ||| VBN
to  ||| S:9553 E:9556 ||| TO
modulate  ||| S:9556 E:9565 ||| CD
IL-1  ||| S:9565 E:9570 ||| CD
action  ||| S:9570 E:9577 ||| NN
on  ||| S:9577 E:9580 ||| IN
human  ||| S:9580 E:9594 ||| JJ
osteoclasts  ||| S:9594 E:9606 ||| NN
in  ||| S:9606 E:9609 ||| IN
vitro ||| S:9609 E:9614 ||| NN
;  ||| S:9614 E:9616 ||| :
estrogen  ||| S:9616 E:9625 ||| FW
administration  ||| S:9625 E:9640 ||| FW
inhibited  ||| S:9640 E:9658 ||| FW
IL-1-mediated  ||| S:9658 E:9672 ||| FW
cytokine  ||| S:9672 E:9681 ||| FW
( ||| S:9681 E:9682 ||| -LRB-
IL-8 ||| S:9682 E:9686 ||| NNP
)  ||| S:9686 E:9688 ||| -RRB-
mRNA  ||| S:9688 E:9693 ||| JJ
induction  ||| S:9693 E:9703 ||| NN
and  ||| S:9703 E:9707 ||| CC
caused  ||| S:9707 E:9722 ||| VBD
increased  ||| S:9722 E:9732 ||| VBN
Ocl  ||| S:9732 E:9736 ||| JJ
apoptosis  ||| S:9736 E:9746 ||| NNS
[  ||| S:9746 E:9748 ||| -LRB-
26 ||| S:9748 E:9750 ||| CD
] ||| S:9750 E:9751 ||| -RRB-
.  ||| S:9751 E:9753 ||| .
When  ||| S:9753 E:9758 ||| WRB
avian  ||| S:9758 E:9764 ||| JJ
Ocl  ||| S:9764 E:9768 ||| NNP
were  ||| S:9768 E:9773 ||| VBD
exposed  ||| S:9773 E:9789 ||| VBN
to  ||| S:9789 E:9792 ||| TO
estradiol  ||| S:9792 E:9802 ||| VB
in  ||| S:9802 E:9805 ||| IN
vitro ||| S:9805 E:9810 ||| NN
,  ||| S:9810 E:9812 ||| ,
the  ||| S:9812 E:9816 ||| DT
Ocl  ||| S:9816 E:9820 ||| JJ
plasma  ||| S:9820 E:9827 ||| NN
membrane  ||| S:9827 E:9836 ||| NNS
became  ||| S:9836 E:9851 ||| VBD
depolarized  ||| S:9851 E:9863 ||| JJ
and  ||| S:9863 E:9867 ||| CC
there  ||| S:9867 E:9873 ||| EX
was  ||| S:9873 E:9877 ||| VBD
a  ||| S:9877 E:9879 ||| DT
marked  ||| S:9879 E:9886 ||| JJ
decrease  ||| S:9886 E:9895 ||| NN
in  ||| S:9895 E:9898 ||| IN
potential ||| S:9898 E:9907 ||| JJ
,  ||| S:9907 E:9917 ||| ,
suggesting  ||| S:9917 E:9928 ||| VBG
that  ||| S:9928 E:9933 ||| DT
estrogen  ||| S:9933 E:9942 ||| NN
may  ||| S:9942 E:9946 ||| MD
regulate  ||| S:9946 E:9955 ||| VB
osteoclasts  ||| S:9955 E:9967 ||| VBN
through  ||| S:9967 E:9983 ||| IN
ion  ||| S:9983 E:9987 ||| JJ
channel  ||| S:9987 E:9995 ||| NN
activities  ||| S:9995 E:10006 ||| NNS
[  ||| S:10006 E:10008 ||| -LRB-
27 ||| S:10008 E:10010 ||| CD
] ||| S:10010 E:10011 ||| -RRB-
.  ||| S:10011 E:10013 ||| .
Estradiol  ||| S:10013 E:10023 ||| NNP
has  ||| S:10023 E:10027 ||| VBZ
also  ||| S:10027 E:10032 ||| RB
been  ||| S:10032 E:10037 ||| VBN
shown  ||| S:10037 E:10051 ||| VBN
to  ||| S:10051 E:10054 ||| TO
inhibit  ||| S:10054 E:10062 ||| VB
acid  ||| S:10062 E:10067 ||| JJ
production  ||| S:10067 E:10078 ||| NN
in  ||| S:10078 E:10081 ||| IN
avian  ||| S:10081 E:10087 ||| JJ
Ocl  ||| S:10087 E:10091 ||| NNP
[  ||| S:10091 E:10093 ||| -LRB-
28 ||| S:10093 E:10095 ||| CD
] ||| S:10095 E:10096 ||| -RRB-
.  ||| S:10096 E:10098 ||| .
The  ||| S:10098 E:10102 ||| DT
human  ||| S:10102 E:10116 ||| JJ
pre-Ocl  ||| S:10116 E:10124 ||| JJ
cell  ||| S:10124 E:10129 ||| NN
line  ||| S:10129 E:10134 ||| NN
FLG  ||| S:10134 E:10138 ||| NNP
29.1  ||| S:10138 E:10143 ||| NNP
has  ||| S:10143 E:10147 ||| VBZ
specific  ||| S:10147 E:10156 ||| JJ
binding  ||| S:10156 E:10164 ||| JJ
sites  ||| S:10164 E:10170 ||| NNS
to  ||| S:10170 E:10181 ||| TO
17β-estradiol  ||| S:10181 E:10195 ||| CD
on  ||| S:10195 E:10198 ||| IN
the  ||| S:10198 E:10202 ||| DT
cell  ||| S:10202 E:10207 ||| NN
surface ||| S:10207 E:10214 ||| NN
,  ||| S:10214 E:10216 ||| ,
and  ||| S:10216 E:10220 ||| CC
estradiol  ||| S:10220 E:10230 ||| JJ
exposure  ||| S:10230 E:10247 ||| NN
increases  ||| S:10247 E:10257 ||| VBZ
the  ||| S:10257 E:10261 ||| DT
cellular  ||| S:10261 E:10270 ||| JJ
pH ||| S:10270 E:10272 ||| NN
,  ||| S:10272 E:10274 ||| ,
cAMP ||| S:10274 E:10278 ||| NNP
,  ||| S:10278 E:10280 ||| ,
cGMP  ||| S:10280 E:10285 ||| JJ
and  ||| S:10285 E:10289 ||| CC
intracellular  ||| S:10289 E:10311 ||| JJ
calcium  ||| S:10311 E:10319 ||| NN
[  ||| S:10319 E:10321 ||| -LRB-
29 ||| S:10321 E:10323 ||| CD
] ||| S:10323 E:10324 ||| -RRB-
.  ||| S:10324 E:10334 ||| .
In  ||| S:10334 E:10337 ||| IN
vivo  ||| S:10337 E:10342 ||| JJ
work  ||| S:10342 E:10347 ||| NN
by  ||| S:10347 E:10350 ||| IN
Jilka  ||| S:10350 E:10356 ||| NNP
et  ||| S:10356 E:10359 ||| FW
al  ||| S:10359 E:10362 ||| FW
has  ||| S:10362 E:10366 ||| VBZ
shown  ||| S:10366 E:10372 ||| VBN
that  ||| S:10372 E:10377 ||| IN
Il-6  ||| S:10377 E:10382 ||| NNP
can  ||| S:10382 E:10394 ||| MD
prevent  ||| S:10394 E:10402 ||| VB
the  ||| S:10402 E:10406 ||| DT
bone  ||| S:10406 E:10411 ||| NN
loss  ||| S:10411 E:10416 ||| NN
associated  ||| S:10416 E:10427 ||| VBN
with  ||| S:10427 E:10432 ||| IN
ovariectomy  ||| S:10432 E:10444 ||| NN
in  ||| S:10444 E:10447 ||| IN
the  ||| S:10447 E:10459 ||| DT
mouse  ||| S:10459 E:10465 ||| NN
model  ||| S:10465 E:10471 ||| NN
[  ||| S:10471 E:10473 ||| -LRB-
30 ||| S:10473 E:10475 ||| CD
] ||| S:10475 E:10476 ||| -RRB-
.  ||| S:10476 E:10478 ||| .
Girasole  ||| S:10478 E:10487 ||| FW
et  ||| S:10487 E:10490 ||| FW
al  ||| S:10490 E:10493 ||| FW
have  ||| S:10493 E:10498 ||| VBP
recently  ||| S:10498 E:10507 ||| RB
shown  ||| S:10507 E:10513 ||| VBN
that  ||| S:10513 E:10526 ||| IN
production  ||| S:10526 E:10537 ||| NN
of  ||| S:10537 E:10540 ||| IN
IL-6  ||| S:10540 E:10545 ||| NNP
is  ||| S:10545 E:10548 ||| VBZ
inhibited  ||| S:10548 E:10558 ||| VBN
in  ||| S:10558 E:10561 ||| IN
vitro  ||| S:10561 E:10567 ||| NN
by  ||| S:10567 E:10570 ||| IN
exposure  ||| S:10570 E:10579 ||| NN
of  ||| S:10579 E:10590 ||| IN
marrow  ||| S:10590 E:10597 ||| JJ
cells  ||| S:10597 E:10603 ||| NNS
to  ||| S:10603 E:10606 ||| TO
17β-estradiol ||| S:10606 E:10619 ||| CD
;  ||| S:10619 E:10621 ||| :
cultures  ||| S:10621 E:10630 ||| NNS
of  ||| S:10630 E:10633 ||| IN
mouse  ||| S:10633 E:10639 ||| NN
bone  ||| S:10639 E:10644 ||| NN
cells  ||| S:10644 E:10658 ||| NNS
showed  ||| S:10658 E:10665 ||| VBD
suppressed  ||| S:10665 E:10676 ||| VBN
osteoclast  ||| S:10676 E:10687 ||| JJ
development  ||| S:10687 E:10699 ||| NN
when  ||| S:10699 E:10704 ||| WRB
exposed  ||| S:10704 E:10712 ||| VBN
to  ||| S:10712 E:10723 ||| TO
either  ||| S:10723 E:10730 ||| DT
17β-estradiol  ||| S:10730 E:10744 ||| NNP
or  ||| S:10744 E:10747 ||| CC
a  ||| S:10747 E:10749 ||| DT
neutralizing  ||| S:10749 E:10762 ||| JJ
antibody  ||| S:10762 E:10771 ||| NN
to  ||| S:10771 E:10774 ||| TO
Il-6  ||| S:10774 E:10779 ||| CD
[  ||| S:10779 E:10789 ||| -LRB-
31 ||| S:10789 E:10791 ||| CD
] ||| S:10791 E:10792 ||| -RRB-
.  ||| S:10792 E:10794 ||| .
Future  ||| S:10794 E:10801 ||| NN
in  ||| S:10801 E:10804 ||| IN
vivo  ||| S:10804 E:10809 ||| JJ
studies  ||| S:10809 E:10817 ||| NNS
combining  ||| S:10817 E:10827 ||| VBG
estradiol  ||| S:10827 E:10837 ||| NNS
and  ||| S:10837 E:10849 ||| CC
selected  ||| S:10849 E:10858 ||| JJ
interleukins  ||| S:10858 E:10871 ||| NN
may  ||| S:10871 E:10875 ||| MD
further  ||| S:10875 E:10883 ||| RB
elucidate  ||| S:10883 E:10893 ||| VB
how  ||| S:10893 E:10897 ||| WRB
the  ||| S:10897 E:10901 ||| DT
network  ||| S:10901 E:10917 ||| NN
of  ||| S:10917 E:10920 ||| IN
signals  ||| S:10920 E:10928 ||| NNS
from  ||| S:10928 E:10933 ||| IN
the  ||| S:10933 E:10937 ||| DT
marrow  ||| S:10937 E:10944 ||| JJ
microenvironment  ||| S:10944 E:10961 ||| NN
influences  ||| S:10961 E:10972 ||| VBZ
both  ||| S:10972 E:10985 ||| DT
Ocl  ||| S:10985 E:10989 ||| JJ
development  ||| S:10989 E:11001 ||| NN
and  ||| S:11001 E:11005 ||| CC
Ocl  ||| S:11005 E:11009 ||| NNP
function ||| S:11009 E:11017 ||| NN
.  ||| S:11017 E:11041 ||| .
Conclusions  ||| S:11041 E:11061 ||| NNP
Findings  ||| S:11061 E:11070 ||| NNP
extend  ||| S:11070 E:11077 ||| VB
our  ||| S:11077 E:11081 ||| PRP$
understanding  ||| S:11081 E:11095 ||| NN
of  ||| S:11095 E:11098 ||| IN
osteoclast  ||| S:11098 E:11117 ||| JJ
structure  ||| S:11117 E:11127 ||| NN
and  ||| S:11127 E:11131 ||| CC
function  ||| S:11131 E:11140 ||| NN
in  ||| S:11140 E:11143 ||| IN
the  ||| S:11143 E:11147 ||| DT
mouse  ||| S:11147 E:11153 ||| NN
exposed  ||| S:11153 E:11161 ||| VBN
in  ||| S:11161 E:11164 ||| IN
vivo  ||| S:11164 E:11169 ||| VBG
to  ||| S:11169 E:11172 ||| TO
high  ||| S:11172 E:11185 ||| JJ
doses  ||| S:11185 E:11191 ||| NNS
of  ||| S:11191 E:11194 ||| IN
estrogen ||| S:11194 E:11202 ||| NN
.  ||| S:11202 E:11204 ||| .
Ultrastructural  ||| S:11204 E:11220 ||| JJ
examination  ||| S:11220 E:11232 ||| NN
showed  ||| S:11232 E:11239 ||| VBD
that  ||| S:11239 E:11252 ||| DT
osteoclasts  ||| S:11252 E:11264 ||| NN
from  ||| S:11264 E:11269 ||| IN
estrogen-treated  ||| S:11269 E:11286 ||| JJ
mice  ||| S:11286 E:11291 ||| NNS
were  ||| S:11291 E:11296 ||| VBD
unable  ||| S:11296 E:11303 ||| JJ
to  ||| S:11303 E:11306 ||| TO
seal  ||| S:11306 E:11319 ||| VB
against  ||| S:11319 E:11327 ||| IN
the  ||| S:11327 E:11331 ||| DT
bone  ||| S:11331 E:11336 ||| NN
surface  ||| S:11336 E:11344 ||| NN
and  ||| S:11344 E:11348 ||| CC
were  ||| S:11348 E:11353 ||| VBD
unable  ||| S:11353 E:11360 ||| JJ
to  ||| S:11360 E:11363 ||| TO
form  ||| S:11363 E:11368 ||| VB
ruffled  ||| S:11368 E:11384 ||| JJ
borders ||| S:11384 E:11391 ||| NNS
.  ||| S:11391 E:11415 ||| .
Materials  ||| S:11415 E:11425 ||| NNS
and  ||| S:11425 E:11429 ||| CC
Methods  ||| S:11429 E:11445 ||| NNP
B6D2F1  ||| S:11445 E:11452 ||| NNP
mice  ||| S:11452 E:11457 ||| NNS
were  ||| S:11457 E:11462 ||| VBD
selected  ||| S:11462 E:11471 ||| VBN
for  ||| S:11471 E:11475 ||| IN
this  ||| S:11475 E:11480 ||| DT
study  ||| S:11480 E:11486 ||| NN
based  ||| S:11486 E:11492 ||| VBN
upon  ||| S:11492 E:11497 ||| IN
the  ||| S:11497 E:11509 ||| DT
following  ||| S:11509 E:11519 ||| JJ
criteria ||| S:11519 E:11527 ||| NNS
.  ||| S:11527 E:11529 ||| .
The  ||| S:11529 E:11533 ||| DT
C57BL ||| S:11533 E:11538 ||| CD
/ ||| S:11538 E:11539 ||| CD
6  ||| S:11539 E:11541 ||| CD
mouse  ||| S:11541 E:11547 ||| NN
is  ||| S:11547 E:11550 ||| VBZ
positive  ||| S:11550 E:11559 ||| JJ
for  ||| S:11559 E:11563 ||| IN
the  ||| S:11563 E:11575 ||| DT
NK  ||| S:11575 E:11578 ||| NNP
1.1  ||| S:11578 E:11582 ||| CD
epitope  ||| S:11582 E:11590 ||| NNS
but  ||| S:11590 E:11594 ||| CC
from  ||| S:11594 E:11599 ||| IN
previous  ||| S:11599 E:11608 ||| JJ
unpublished  ||| S:11608 E:11620 ||| JJ
data  ||| S:11620 E:11625 ||| NNS
we  ||| S:11625 E:11628 ||| PRP
found  ||| S:11628 E:11642 ||| VBD
that  ||| S:11642 E:11647 ||| IN
the  ||| S:11647 E:11651 ||| DT
C57BL ||| S:11651 E:11656 ||| CD
/ ||| S:11656 E:11657 ||| CD
6  ||| S:11657 E:11659 ||| CD
responded  ||| S:11659 E:11669 ||| VBD
poorly  ||| S:11669 E:11676 ||| RB
to  ||| S:11676 E:11679 ||| TO
estradiol ||| S:11679 E:11688 ||| VB
.  ||| S:11688 E:11690 ||| .
From  ||| S:11690 E:11703 ||| IN
previous  ||| S:11703 E:11712 ||| JJ
hybrid  ||| S:11712 E:11719 ||| JJ
resistance  ||| S:11719 E:11730 ||| NN
studies  ||| S:11730 E:11738 ||| NNS
we  ||| S:11738 E:11741 ||| PRP
had  ||| S:11741 E:11745 ||| VBD
historical  ||| S:11745 E:11756 ||| JJ
data  ||| S:11756 E:11769 ||| NNS
that  ||| S:11769 E:11774 ||| IN
the  ||| S:11774 E:11778 ||| DT
B6D2F1  ||| S:11778 E:11785 ||| JJ
mouse  ||| S:11785 E:11791 ||| NN
would  ||| S:11791 E:11797 ||| MD
be  ||| S:11797 E:11800 ||| VB
positive  ||| S:11800 E:11809 ||| JJ
for  ||| S:11809 E:11813 ||| IN
the  ||| S:11813 E:11817 ||| DT
NK  ||| S:11817 E:11820 ||| NNP
1.1  ||| S:11820 E:11832 ||| CD
epitope  ||| S:11832 E:11840 ||| NNS
and  ||| S:11840 E:11844 ||| CC
respond  ||| S:11844 E:11852 ||| VB
well  ||| S:11852 E:11857 ||| RB
to  ||| S:11857 E:11860 ||| TO
the  ||| S:11860 E:11864 ||| DT
estradiol ||| S:11864 E:11873 ||| NN
.  ||| S:11873 E:11875 ||| .
B6D2F1  ||| S:11875 E:11882 ||| NNP
male  ||| S:11882 E:11887 ||| JJ
mice  ||| S:11887 E:11900 ||| NNS
aged  ||| S:11900 E:11905 ||| VBN
4-5  ||| S:11905 E:11909 ||| CD
weeks  ||| S:11909 E:11915 ||| NNS
were  ||| S:11915 E:11920 ||| VBD
implanted  ||| S:11920 E:11930 ||| VBN
for  ||| S:11930 E:11934 ||| IN
at  ||| S:11934 E:11937 ||| IN
least  ||| S:11937 E:11943 ||| JJS
12  ||| S:11943 E:11946 ||| CD
weeks  ||| S:11946 E:11952 ||| NNS
with  ||| S:11952 E:11965 ||| IN
silastic  ||| S:11965 E:11974 ||| NNS
tubing  ||| S:11974 E:11981 ||| VBP
filled  ||| S:11981 E:11988 ||| VBN
with  ||| S:11988 E:11993 ||| IN
15  ||| S:11993 E:11996 ||| CD
mg  ||| S:11996 E:11999 ||| CD
17β-estradiol  ||| S:11999 E:12013 ||| CD
[  ||| S:12013 E:12015 ||| -LRB-
32 ||| S:12015 E:12017 ||| CD
,  ||| S:12017 E:12019 ||| ,
33 ||| S:12019 E:12021 ||| CD
,  ||| S:12021 E:12031 ||| ,
34 ||| S:12031 E:12033 ||| CD
,  ||| S:12033 E:12035 ||| ,
35 ||| S:12035 E:12037 ||| CD
] ||| S:12037 E:12038 ||| -RRB-
;  ||| S:12038 E:12040 ||| :
age-matched  ||| S:12040 E:12052 ||| JJ
controls  ||| S:12052 E:12061 ||| NNS
received  ||| S:12061 E:12070 ||| VBD
empty  ||| S:12070 E:12076 ||| JJ
tubing ||| S:12076 E:12082 ||| NN
.  ||| S:12082 E:12084 ||| .
NK  ||| S:12084 E:12095 ||| NNP
cytolytic  ||| S:12095 E:12105 ||| NN
functions  ||| S:12105 E:12115 ||| NNS
disappeared  ||| S:12115 E:12127 ||| VBD
in  ||| S:12127 E:12130 ||| IN
estradiol-treated  ||| S:12130 E:12148 ||| JJ
mice  ||| S:12148 E:12161 ||| NNS
by  ||| S:12161 E:12164 ||| IN
8  ||| S:12164 E:12166 ||| CD
weeks ||| S:12166 E:12171 ||| NNS
.  ||| S:12171 E:12173 ||| .
Previous  ||| S:12173 E:12182 ||| JJ
work  ||| S:12182 E:12187 ||| NN
with  ||| S:12187 E:12192 ||| IN
the  ||| S:12192 E:12196 ||| DT
model  ||| S:12196 E:12202 ||| NN
by  ||| S:12202 E:12205 ||| IN
Roubinian  ||| S:12205 E:12215 ||| NNP
et  ||| S:12215 E:12218 ||| NNP
al  ||| S:12218 E:12229 ||| NN
showed  ||| S:12229 E:12236 ||| VBD
that  ||| S:12236 E:12241 ||| DT
administration  ||| S:12241 E:12256 ||| NN
of  ||| S:12256 E:12259 ||| IN
5-6.5  ||| S:12259 E:12265 ||| CD
mg  ||| S:12265 E:12268 ||| JJ
estradiol  ||| S:12268 E:12278 ||| NN
by  ||| S:12278 E:12281 ||| IN
this  ||| S:12281 E:12294 ||| DT
method  ||| S:12294 E:12301 ||| NN
returned  ||| S:12301 E:12310 ||| VBD
estrogen  ||| S:12310 E:12319 ||| JJ
levels  ||| S:12319 E:12326 ||| NNS
to  ||| S:12326 E:12329 ||| TO
normal  ||| S:12329 E:12336 ||| JJ
in  ||| S:12336 E:12339 ||| IN
ovariectomized  ||| S:12339 E:12362 ||| JJ
mice  ||| S:12362 E:12367 ||| NNS
for  ||| S:12367 E:12371 ||| IN
more  ||| S:12371 E:12376 ||| JJR
than  ||| S:12376 E:12381 ||| IN
3  ||| S:12381 E:12383 ||| CD
months  ||| S:12383 E:12390 ||| NNS
[  ||| S:12390 E:12392 ||| -LRB-
36 ||| S:12392 E:12394 ||| CD
] ||| S:12394 E:12395 ||| -RRB-
.  ||| S:12395 E:12397 ||| .
Seaman  ||| S:12397 E:12404 ||| NNP
et  ||| S:12404 E:12407 ||| FW
al  ||| S:12407 E:12410 ||| FW
has  ||| S:12410 E:12414 ||| VBZ
also  ||| S:12414 E:12427 ||| RB
reported  ||| S:12427 E:12436 ||| VBN
that  ||| S:12436 E:12441 ||| IN
administration  ||| S:12441 E:12456 ||| NN
15  ||| S:12456 E:12459 ||| CD
mg  ||| S:12459 E:12462 ||| JJ
estradiol  ||| S:12462 E:12472 ||| NN
in  ||| S:12472 E:12475 ||| IN
this  ||| S:12475 E:12480 ||| DT
model  ||| S:12480 E:12494 ||| NN
was  ||| S:12494 E:12498 ||| VBD
capable  ||| S:12498 E:12506 ||| JJ
of  ||| S:12506 E:12509 ||| IN
raising  ||| S:12509 E:12517 ||| VBG
estradiol  ||| S:12517 E:12527 ||| NN
to  ||| S:12527 E:12530 ||| TO
9  ||| S:12530 E:12532 ||| CD
times  ||| S:12532 E:12538 ||| NNS
the  ||| S:12538 E:12542 ||| DT
normal  ||| S:12542 E:12557 ||| JJ
level  ||| S:12557 E:12563 ||| NN
[  ||| S:12563 E:12565 ||| -LRB-
37 ||| S:12565 E:12567 ||| CD
,  ||| S:12567 E:12569 ||| ,
38 ||| S:12569 E:12571 ||| CD
] ||| S:12571 E:12572 ||| -RRB-
.  ||| S:12572 E:12582 ||| .
At  ||| S:12582 E:12585 ||| IN
8-18  ||| S:12585 E:12590 ||| CD
weeks  ||| S:12590 E:12596 ||| NNS
post-implantation ||| S:12596 E:12613 ||| JJ
,  ||| S:12613 E:12615 ||| ,
euthanasia  ||| S:12615 E:12626 ||| NN
was  ||| S:12626 E:12638 ||| VBD
performed  ||| S:12638 E:12648 ||| VBN
( ||| S:12648 E:12649 ||| -LRB-
CO  ||| S:12649 E:12661 ||| NNP
2  ||| S:12661 E:12663 ||| CD
inhalation ||| S:12663 E:12673 ||| CD
)  ||| S:12673 E:12675 ||| -RRB-
and  ||| S:12675 E:12679 ||| CC
femurs  ||| S:12679 E:12686 ||| NNS
were  ||| S:12686 E:12691 ||| VBD
harvested  ||| S:12691 E:12709 ||| VBN
from  ||| S:12709 E:12714 ||| IN
13  ||| S:12714 E:12717 ||| CD
control  ||| S:12717 E:12725 ||| NN
and  ||| S:12725 E:12729 ||| CC
33  ||| S:12729 E:12732 ||| CD
estradiol-treated  ||| S:12732 E:12750 ||| JJ
mice ||| S:12750 E:12754 ||| NNS
.  ||| S:12754 E:12764 ||| .
Cross-sections  ||| S:12764 E:12779 ||| JJ
of  ||| S:12779 E:12782 ||| IN
the  ||| S:12782 E:12786 ||| DT
femur  ||| S:12786 E:12792 ||| NN
and  ||| S:12792 E:12796 ||| CC
sections  ||| S:12796 E:12805 ||| NNS
of  ||| S:12805 E:12808 ||| IN
femoral  ||| S:12808 E:12824 ||| JJ
metaphyses  ||| S:12824 E:12835 ||| NN
and  ||| S:12835 E:12839 ||| CC
epiphyses  ||| S:12839 E:12849 ||| NNS
were  ||| S:12849 E:12854 ||| VBD
studied ||| S:12854 E:12861 ||| VBN
.  ||| S:12861 E:12863 ||| .
For  ||| S:12863 E:12867 ||| IN
light  ||| S:12867 E:12881 ||| JJ
microscopy ||| S:12881 E:12891 ||| NN
,  ||| S:12891 E:12893 ||| ,
specimens  ||| S:12893 E:12903 ||| NNS
were  ||| S:12903 E:12908 ||| VBD
either  ||| S:12908 E:12915 ||| RB
fixed  ||| S:12915 E:12921 ||| VBN
in  ||| S:12921 E:12924 ||| IN
10 ||| S:12924 E:12926 ||| CD
%  ||| S:12926 E:12928 ||| NN
neutral  ||| S:12928 E:12944 ||| JJ
buffered  ||| S:12944 E:12953 ||| JJ
formalin ||| S:12953 E:12961 ||| NN
,  ||| S:12961 E:12963 ||| ,
decalcified  ||| S:12963 E:12975 ||| NN
and  ||| S:12975 E:12979 ||| CC
embedded  ||| S:12979 E:12988 ||| VBN
in  ||| S:12988 E:12991 ||| IN
paraffin  ||| S:12991 E:13000 ||| NN
or  ||| S:13000 E:13011 ||| CC
processed  ||| S:13011 E:13021 ||| VBN
non-decalcified  ||| S:13021 E:13037 ||| JJ
and  ||| S:13037 E:13041 ||| CC
embedded  ||| S:13041 E:13050 ||| VBN
in  ||| S:13050 E:13053 ||| IN
methyl  ||| S:13053 E:13068 ||| JJ
methacrylate ||| S:13068 E:13080 ||| NN
.  ||| S:13080 E:13082 ||| .
For  ||| S:13082 E:13086 ||| IN
ultrastructural  ||| S:13086 E:13102 ||| JJ
studies ||| S:13102 E:13109 ||| NNS
,  ||| S:13109 E:13111 ||| ,
specimens  ||| S:13111 E:13121 ||| NNS
were  ||| S:13121 E:13134 ||| VBD
fixed  ||| S:13134 E:13140 ||| VBN
in  ||| S:13140 E:13143 ||| IN
Karnovsky ||| S:13143 E:13152 ||| NNP
's  ||| S:13152 E:13155 ||| POS
fixative ||| S:13155 E:13163 ||| NN
,  ||| S:13163 E:13165 ||| ,
post-fixed  ||| S:13165 E:13176 ||| JJ
in  ||| S:13176 E:13179 ||| IN
osmium  ||| S:13179 E:13194 ||| JJ
tetroxide ||| S:13194 E:13203 ||| NN
,  ||| S:13203 E:13205 ||| ,
decalcified ||| S:13205 E:13216 ||| NN
,  ||| S:13216 E:13218 ||| ,
and  ||| S:13218 E:13222 ||| CC
embedded  ||| S:13222 E:13231 ||| VBN
in  ||| S:13231 E:13234 ||| IN
Spurr  ||| S:13234 E:13240 ||| NNP
resin ||| S:13240 E:13245 ||| NN
.  ||| S:13245 E:13247 ||| .
Thin  ||| S:13247 E:13260 ||| JJ
sections  ||| S:13260 E:13269 ||| NNS
were  ||| S:13269 E:13274 ||| VBD
prepared  ||| S:13274 E:13283 ||| VBN
and  ||| S:13283 E:13287 ||| CC
grids  ||| S:13287 E:13293 ||| NNS
were  ||| S:13293 E:13298 ||| VBD
stained  ||| S:13298 E:13306 ||| VBN
with  ||| S:13306 E:13311 ||| IN
uranyl  ||| S:13311 E:13326 ||| JJ
acetate  ||| S:13326 E:13334 ||| NN
and  ||| S:13334 E:13338 ||| CC
lead  ||| S:13338 E:13343 ||| JJ
citrate ||| S:13343 E:13350 ||| NN
.  ||| S:13350 E:13352 ||| .
Sections  ||| S:13352 E:13361 ||| NNS
were  ||| S:13361 E:13366 ||| VBD
viewed  ||| S:13366 E:13373 ||| VBN
on  ||| S:13373 E:13376 ||| IN
a  ||| S:13376 E:13386 ||| DT
Phillips  ||| S:13386 E:13395 ||| NNP
CM10  ||| S:13395 E:13400 ||| FW
transmission  ||| S:13400 E:13413 ||| FW
electron  ||| S:13413 E:13422 ||| FW
microscope ||| S:13422 E:13432 ||| FW
.  ||| S:13432 E:13434 ||| .
Light  ||| S:13434 E:13448 ||| JJ
microscopic  ||| S:13448 E:13460 ||| JJ
sections  ||| S:13460 E:13469 ||| NNS
were  ||| S:13469 E:13474 ||| VBD
evaluated  ||| S:13474 E:13484 ||| VBN
with  ||| S:13484 E:13489 ||| IN
quantitative  ||| S:13489 E:13510 ||| JJ
histomorphometry  ||| S:13510 E:13527 ||| NNS
using  ||| S:13527 E:13533 ||| VBG
OsteoMeasure  ||| S:13533 E:13546 ||| JJ
software  ||| S:13546 E:13555 ||| NN
( ||| S:13555 E:13556 ||| -LRB-
OsteoMetrics ||| S:13556 E:13568 ||| NNP
,  ||| S:13568 E:13578 ||| ,
Inc. ||| S:13578 E:13582 ||| NNP
,  ||| S:13582 E:13584 ||| ,
Decatur ||| S:13584 E:13591 ||| NNP
,  ||| S:13591 E:13593 ||| ,
GA ||| S:13593 E:13595 ||| NNP
) ||| S:13595 E:13596 ||| -RRB-
.  ||| S:13596 E:13598 ||| .
Tartrate-resistant  ||| S:13598 E:13617 ||| JJ
acid  ||| S:13617 E:13622 ||| NN
phosphatase  ||| S:13622 E:13642 ||| NNS
( ||| S:13642 E:13643 ||| -LRB-
TRAP ||| S:13643 E:13647 ||| NNP
)  ||| S:13647 E:13649 ||| -RRB-
localization  ||| S:13649 E:13662 ||| NN
was  ||| S:13662 E:13666 ||| VBD
performed  ||| S:13666 E:13676 ||| VBN
to  ||| S:13676 E:13679 ||| TO
identify  ||| S:13679 E:13688 ||| VB
osteoclasts  ||| S:13688 E:13708 ||| VBN
with  ||| S:13708 E:13713 ||| IN
light  ||| S:13713 E:13719 ||| JJ
microscopy ||| S:13719 E:13729 ||| NN
.  ||| S:13729 E:13731 ||| .
Protocols  ||| S:13731 E:13741 ||| NNP
were  ||| S:13741 E:13746 ||| VBD
approved  ||| S:13746 E:13755 ||| VBN
by  ||| S:13755 E:13758 ||| IN
the  ||| S:13758 E:13770 ||| DT
appropriate  ||| S:13770 E:13782 ||| JJ
Institutional  ||| S:13782 E:13796 ||| NNP
Animal  ||| S:13796 E:13803 ||| NNP
Care  ||| S:13803 E:13808 ||| NNP
and  ||| S:13808 E:13812 ||| CC
Use  ||| S:13812 E:13824 ||| NNP
Committee ||| S:13824 E:13833 ||| NNP
.  ||| S:13833 E:13843 ||| .
Statistical  ||| S:13843 E:13855 ||| JJ
analysis  ||| S:13855 E:13864 ||| NN
of  ||| S:13864 E:13867 ||| IN
quantitative  ||| S:13867 E:13880 ||| JJ
histomorphometric  ||| S:13880 E:13906 ||| JJ
data  ||| S:13906 E:13911 ||| NNS
used  ||| S:13911 E:13916 ||| VBN
standard  ||| S:13916 E:13925 ||| JJ
statistical  ||| S:13925 E:13937 ||| JJ
methods ||| S:13937 E:13944 ||| NNS
;  ||| S:13944 E:13946 ||| :
means  ||| S:13946 E:13952 ||| NNS
and  ||| S:13952 E:13956 ||| CC
standard  ||| S:13956 E:13973 ||| JJ
deviations  ||| S:13973 E:13984 ||| NNS
were  ||| S:13984 E:13989 ||| VBD
calculated ||| S:13989 E:13999 ||| VBN
.  ||| S:13999 E:14001 ||| .
Unpaired  ||| S:14001 E:14010 ||| NNP
t-tests  ||| S:14010 E:14018 ||| NNP
were  ||| S:14018 E:14023 ||| VBD
used  ||| S:14023 E:14028 ||| VBN
to  ||| S:14028 E:14039 ||| TO
test  ||| S:14039 E:14044 ||| VB
for  ||| S:14044 E:14048 ||| IN
differences  ||| S:14048 E:14060 ||| NNS
between  ||| S:14060 E:14068 ||| IN
means ||| S:14068 E:14073 ||| NNS
;  ||| S:14073 E:14075 ||| :
a  ||| S:14075 E:14077 ||| DT
p-value  ||| S:14077 E:14085 ||| JJ
of  ||| S:14085 E:14088 ||| IN
< ||| S:14088 E:14089 ||| SYM
0.05  ||| S:14089 E:14102 ||| CD
was  ||| S:14102 E:14106 ||| VBD
considered  ||| S:14106 E:14117 ||| VBN
statistically  ||| S:14117 E:14131 ||| RB
significant ||| S:14131 E:14142 ||| JJ
.  ||| S:14142 E:14159 ||| .
